|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/10/15 ¤W¤È 01:05:51
|
¥»ª©°w¹ï¯E¹©°ò¥»±°Q½×Àù¯gªvÀø¡B§K¬ÌÀøªk¡BÁ{§É¸ê°T¡F¯E¹©¦U¶µ²£«~¬ãµo¶i«×°lÂÜ°Q½×¡FÄvª§¹ï¤â°ÊºA»P¦U¤è¶i«×°lÂÜ¡C¦P®É¯Ç¤Jª©¡uOBI-822¡BOBI-833¥H¥~ªº²£«~¡vªº¤º®e¡C·q½Ð¦U¦ì¤j¤j´N¥H¤WijÃDªº°ò¥»±Ä~Äò´£¨Ñ´¼¼z¡C ¥un¨¥¤§¦³ª«¡A¥ß½×¦³¾Ú¡A¦hªÅ¬ÒÅwªï¡C ¥»ºô»{¬°©¹«áY¹J¨ìÃþ¦üªºª¬ªp¡A¥i¥H¥Ñ¸Ó¶}ª©¤§¥D¤H¨Ó§P©w¡A ¨Ò¦p¦¹ª©´N¥ÑCliff¤j¤j¨Ó§P©wµo¨¥¤º®e¬O§_²Å¦X¸Óª©¤º®e¡A Y¥D¤H»{©w¤£²Å¡A¦A¥Ñ¥»ºô¤©¥H§R°£¡A¦p¦ó¡HBYª©¥D
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2014/12/29 ¤U¤È 03:10:06²Ä 120 ½g¦^À³
|
ªü¬Â¤j ±zªºÂå®vªB¤Í ¸Ó¬O°Ñ»P¸ÕÅç±wªÌªº¥DªvÂå®v ¥i§_½Ð¥L´yz ±wªÌ¸~½F¤j¤pÀH®É¶¡ªºÅÜ¤Æ ¬O¤@ª½ÁY¤p¨ì3-3.5¤½¤À ÁÙ¬O¦³ÁY¨ì§ó¤p ¦AÅܤj¨ì³oӤؤo? ÁÙ¦³¸Ó¨â¦ì±wªÌªì¤J¸ÕÅç®É¬ONED ÁÙ¬OSD ? ·PÁ±z! |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2014/12/29 ¤U¤È 02:11:13²Ä 119 ½g¦^À³
|
ªü¬Â¤j¡A ¤Ó·PÁ¤F¡I ¨º¤p§Ì¦A°Ý¤@Ó°ÝÃD ±z»¡¡y¥´¨ìÃĨº2¤H¨ÅÀù²¾Âà¨ìªÍ¤Î¨x¬ù5¤½¤À¥´ÃÄ«á¬ù1¦~¥b¸~½FÁY¤p3_3.5¤½¤À¨ÃµL©úÅã°Æ§@¥Î.¡z ¥´ÃÄ«á¬ù¤@¦~¥bªÍ¤Î¨xªº¸~½FÁY¤p¨ì3~3.5¤½¤À¡A³o¬O¶i¤JÁ{§É¹êÅç«á¦h¤[µo¥Íªº¨Æ±¡¡H3Ó¤ë¡H6Ó¤ë¡H¤@¦~©Î¤@¦~¥b¡H¤p§Ìªº·N«ä¬O¡E±q¥´²Ä¤@°w«á¡Aªá¤F¦h¤[ªº®É¶¡ªÍ¤Î¨xªº¸~½F¹F¨ìÁY¤p¨ì3~3.5¤½¤Àªºª¬ºA¡H¤§«á´N°±¤î¦b³oÓª¬ºA¡C ªÍ¤Î¨x¨âÓ¾¹©xªº¸~½FÁY¤pªºÅܤƱ¡ªp¬O®t¤£¦hªº±¡ªp¶Ü¡HÁÙ¬OªÍ¤ñ¸û¦n©Î¨x¤ñ¸û¦n¡H ¨Å©Ðªº¸~½FÅܤƪº±¡ªp¦³¤ñªÍ¤Î¨xªº±¡ªp¦nÁÙ¬O®t¡H ¦A¦¸·PÁ¡I |
|
|
·|û¡Gdavidh10137720 µoªí®É¶¡:2014/12/29 ¤U¤È 02:10:22²Ä 118 ½g¦^À³
|
ÁÂÁªü¬Â¤j©Ò´£¨Ñ¦³ÃöOBI-822Á{§É¥|¤Hªºµ²ªG¡A¤£³×¬O¯E¤Í³Ì¨Îªº¸t½Ï§ª«¡AY¤è«Kªº¸Ü,¥i§_À°¦£°Ý¸ÓÂå¥Íª¾§_¨ä¥LÂå°|ªºÂå¥Í¦³µL¬ÛÃöªºÆ[¬dµ²ªG?¦]¦P¬°°ü¬ì¤j¤Ò¡AÁö¸óÂå°|¡A¦ý¤´¥i¯àɾǷ|©Î¦P¾Ç¤§Ãö«Y¡A¦Ó¶¡±µ©Î¤£¸g·N¦ÓÅ¥¨ì³o¤è±ªº«H®§©O!! |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2014/12/29 ¤U¤È 01:51:10²Ä 117 ½g¦^À³
|
¦U¦ì¤j¤j¦pªG¦³¥ô¦ó°ÝÃD,§Ú¤@°_°Ý¥L. |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2014/12/29 ¤U¤È 01:09:55²Ä 116 ½g¦^À³
|
ªü¬Â¤j¡A ±z»¡¡y¥´¨ìÃĨº2¤H¨ÅÀù²¾Âà¨ìªÍ¤Î¨x¬ù5¤½¤À¥´ÃÄ«á¬ù1¦~¥b¸~½FÁY¤p3_3.5¤½¤À¨ÃµL©úÅã°Æ§@¥Î.¡z ¤p§Ì¬ðµM·Q¨ì¤@Ó°ÝÃD ²á¤Ñ¹Lµ{¤¤¦³´£¨ì¡A쥻ªº¨ÅÀù¸~½FªºÅܤƶܡH ªÍ¤Î¨x¬OÂಾ¹L¥hªº¡AªvÀø®ÄªG¬O5cm¡÷3~3.5cm ¨ºì¥»¨Å©Ð¤Wªº¸~½F©O¡H ¬O¤â³N¤Á°£°®²b«á°Ñ»PªvÀøºû«ù¨S¦³¸~½Fªºª¬ºA¡H ÁÙ¬O¨Å©Ð¤]¦³5CMªº¸~½F¡AªvÀø«á¤]ÁY¤p¨ì3~3.5CM¡H ³o¤£¤@©w®e©ö¦^µª ¥i§_³Â·Ð±z·Q¤@¤U¬Q¤Ñªº¹ï¸Ü¡H ¯uªº«Ü·PÁ±z¡I |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2014/12/29 ¤U¤È 12:45:06²Ä 115 ½g¦^À³
|
¤½¥q©xºô¤Wªº¬ãµo¶i®i¡A¤µ¤Ñ¤W¥h¬Ý¤w¸g¨S¦³OBI-888¤F¡A¦³µLª¾±¡ªº¯E¤Í¯à°÷»¡©ú¤@¤U¡A·PÁ !! ÁöµM¤½¶}»¡©ú®Ñ¤WÁÙ¬O¦³´£¨ì888 |
|
|
·|û¡Grabbit10136567 µoªí®É¶¡:2014/12/29 ¤W¤È 10:49:25²Ä 114 ½g¦^À³
|
Hi all, ³o¦¸¦³¤TÓ¤£¤j¬Û¦Pªº¸ê°T¡A©Î³\¬O§Ú¥H«eº|±¼¡A¦ý²Ä3ÂIÅý§Ú¦³ÂIºÃ´b.. 1.ìªø©°pµeµ²§ôÂà ³¯¹a¬z³Õ¤h: ©e°U°õ¦æÀH¾÷¤À°t¡BÂùª¼¡B²Ä¤G´Á ²Ä¤T´ÁÁ{§ÉàPÅç¡A¥HGlobo H-KLH (OPT-822)¥D°Ê§K¬ÌÀøªkªvÀøÂಾ©Ê¨ÅÀù±wªÌ¤§ªþÄݸÕÅç¡C <³o½T»{¥xÆW¯E¹©¦³¦b°µ¤@¨Ç¥Ø«eÁÙ¤£¬°¥~¤H¹Dªº¸ÕÅç¡A±ÀºVÀ³¸Ó¥DnÁÙ¬O GH ¤ÏÀ³»P¸ÕÅ窺³sµ²Ãö«Y³Ì¦³¥i¯à¡C> 2.°]¹Îªk¤H¥Íª«§Þ ³N¶}µo¤¤¤ß:CRM197 ²ÓM®è»P³J¥Õ½è¥Í²£©e°Upµe <³o¬O¥»ª©¶}ª© Cliff ´£¨ìªº"Âù¯S²§©Ê...." ¬ã¨s³æ¦ì¡A°õ¦æ CRM197¥Í²£p¹º> 3.Åv§Qª÷¡G¨C§Jª÷ÃBx Globo H ¤§¦~«×Á`ÁʶR¶q¡C <³oÓÅv§Qª÷¥]§t¦b 8%? ¤ä¥I¹ï¶H¬°¤¤¬ã°|? ³o¦³¥²nªk»¡·|°Ý°Ý¬Ý> |
|
|
·|û¡GJM10139061 µoªí®É¶¡:2014/12/29 ¤W¤È 10:38:07²Ä 113 ½g¦^À³
|
¤]¤£ª¾ºâ¤£ºâ"¬Ý¨ì¶Â¼v´N¶}ºj": ¥t¤@Ó¥«³õ«Å|ªººÃ¦ü°l§L¡G¥xºÍ(±N¤W¿³Âd),¨â½g¤å³¹¨Ñ°Ñ. ¤£¹L,¬JµM¦³822,ÁÙ»Ýn¥xºÍªºTRX818¶Ü(©Ò¥HTRX818¨S«e³~)?©Î¨ä¹êTRX818¥i¥H¬O»²§U©Ê½è? ½Ð°ª¤â̦³ªÅ¸ÑŪ¤@¤U(©çÁÂ,§ä¨ìªº¸ê®Æ¯uªº«Ü¤Ö) http://richers77018898.pixnet.net/blog/post/393697829 ³Ð³y¥xÆW¥»¤g§Þ³Nȱo±j¯Pª`¥Ø¡A3 ¦~¤º³ÌÀéÄꪺ©ú¬P¥i¯à¬O¥xºÍ http://mag.chinatimes.com/mag-cnt.aspx?artid=24053 2014-04-22 ²Ä201404´Á ¡u¯«ºj¤â¡v¥xºÍ¥Í§Þ 2015 ÀÀµn¿³Âd |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2014/12/29 ¤W¤È 10:02:03²Ä 112 ½g¦^À³
|
¤§«e´¿´£¨ìªº(§ZXÀù)¦¨ªGµoªí·|,11¤ë©µ¦Ü12¤ë,«Ü³øºp³£¨Sµo¥Í¡C ³Ì·sªº»¡ªk¬O:¹A¾ä¦~«e«áµoªí¡C ³o¦¸§Æ±æ¤£·|¦A©µ¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2014/12/29 ¤W¤È 09:56:09²Ä 111 ½g¦^À³
|
³oÓ°T®§ ¦ü¥G¦LÃÒ¤F¤p©_¤jªº±À·Q ¤]¸Ñ¶}¤F¤p§Ìªø¤[¥H¨Ó¤ß¤¤ªººÃ°Ý ¤p§Ì³oÓ²q´ú µLÃö¨Æ¹ê ½Ð¤j®a¬Ý¬Ý´N¦n ÁÂÁÂ! |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2014/12/29 ¤W¤È 09:53:23²Ä 110 ½g¦^À³
|
ÁÂÁÂ¥xÁÞ¡Aµ½¤H¡A²q·Q¡ACliff¡A¤p©_¡Aªü¬Â¡AFaith¡AJMµ¥ÁÙ¦³«Ü¦h¤j¤j¤À¨É¡A³o¨Ç¸ê°T¯u¬O¤ÓÆg¤F 1.Åv§Qª÷¤ñ¥ý«e¹w¦ôªº²Ä¤F³\¦h-->§Q¦h 2.ÃĮĤQ¤ÀÅãµÛ-->1.5¦~¸~½F¤£¦ý¨S¦³Åܤj¤Ï¦ÓÁY¤p¡A¥i¼¦¨S¥´¨ì822ªº±wªÌ´N¨S¨º»ò©¯¹B¤F ©Ò¥H822nºÉ§Ö¤W¥«±Ï¤H¤~¬O 3.350¤j·§¬O©Ò¯à¨£¨ìªº³Ì§CÂI¡A¤p§Ì¥u¦³©¯¦b358¥[½X¤@±i¡A¦ý¬O¦p¤p§Ì©Ò®Æ¤ë©³¤w¸g§_·¥®õ¨ÓÀ³¸Ón·Ç³Æ®i¯Í°ª¸°Õ 400À³¸Ó«Ü§Ö¤Sn¨£¨ì¡A¤Á¤ß¤j³o¦¸À³¸Ó¤~·|¯uªº¤Á¤ß¤§µh§a(¤£µM´N«i´±§ë°°l¦^¨Ó§a) 4.¤½¥q¤w¸g¦b¤½¶}»¡©ú®Ñ¤W¥Î"¬Ì]"¨ÓºÙ©I822/833µ¥¡AÃĮķ|¦p¦óºÉ¦b¤£¨¥¤¤ 2014¬O¦h¨aªº¤@¦~¡A¨H²îªº¡A±¼¸¾÷ªº¡A®ðÃzªº¨Æ¥ó¤£Â_µo¥Í¡A®i±æ2015¡A§Æ±æ°ê»Ú/°ê®a/ªÀ·|/§ë¸ê¯E¹©³£¯à ·½Õ«B¶¶¡A¥¦w¶¶¹E 5.2015¦~¯E¹©¬O§_·|¨ì¹F800¤¸©O¡AÅý«¥Ì¯E¤ÍÄ~Äò¬Ý¤U¥h¡A"Ä~ÄòÅó±ø±ø"¬O¤£Åܪºµw¹D²z ~~ ¯¬ºÖ ¦U¦ì¯E¤Í³£¯à¤ß·Q¨Æ¦¨ ~~ |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/12/29 ¤W¤È 09:41:27²Ä 109 ½g¦^À³
|
ªü¬Â¤j ·PÁ±zªº°T®§ ´c©Ê¸~½F5¤½¤À¤w¬O«D±`ªº¤j¤F ¯àÁY¤pÓ´XÂç¦Ì³£¬O©_ÂݤF ¦n¼F®`§r ·PÁ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2014/12/29 ¤W¤È 09:21:32²Ä 108 ½g¦^À³
|
¤ý£«¬Â¤j ÁÂÁ±zªº½T»{ ¤p§Ì¤§©Ò¥H°Ý³oÓÄø°ÝÃD ¬O°ò©óª½±µ´ú¶q©Ò±o¼Æ¦r °£«D¥²n ¤@¯ë¤H©Î¤£·|¦A¨è·N¥hpºâÁY¤p¦h¤Ö ¬G¦³¦¹°Ý ¦A¦¸·PÁ±z! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2014/12/29 ¤W¤È 08:51:32²Ä 107 ½g¦^À³
|
¤ý£«¬Â¤j ¹ï¤£°_ ¤p§Ì·Q¦A½T»{¤@¤U ¬O¡¨ ÁY¤p3_3.5¤½¤À¡¨? ÁÙ¬OÁY¤p¨ì3_3.5¤½¤À? ·PÁ±z! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/12/29 ¤W¤È 12:43:07²Ä 106 ½g¦^À³
|
µ½¤H¤j §A¤ÀªRªº«Ü²Ó¿°,§¹¥þ¦P·N§Aªº¸ÑŪ,¯E¹©n¥IªºÅv§Qª÷¤ñ·íªìªº·Q¹³¤Ö¤Ó¦h,³o¤£ª¾¥i§_ºâ¬O¤@¶µ¤jªº§Q¦h¡A À³¸Ó¬O¥u¦¬26¦W¨ü¸Õ ¡A¦WÃB¤£¤@©w¥§¡ |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2014/12/29 ¤W¤È 12:23:05²Ä 105 ½g¦^À³
|
¥xÁÞ¤j Faith¤j, «D±`·PÁ±z̪º¼ö¤ß¤À¨É The primary purpose of the clinical trial is to investigate safety and tolerability of escalating doses of OBI-833/OBI-821 in subjects with metastatic incurable solid tumors, such as gastric, lung, colorectal or breast cancer. Meanwhile, the humoral immune responses, i.e.,anti-Globo H IgG and IgM production following administration of OBI-833/OBI-821 will be assessed as the secondary objective of this study. Estimated Enrollment: 26 ¤w¸gµn¿ý¦b ClinicalTrials.gov (A service of U.S. National Institutes of Health)ªºÁ{§É¸ÕÅç, ¹ê»Ú§@Á{§É¸ÕÅç®É, ¸ÕÅ窺Àù¯gºØÃþ¬O§_n§¹¥þ¤@¼Ë? ¦pªG¬O, OBI-833/821¤@´Án°µªº¬OÂಾ©ÊªÍÀù, GÀù, ¤j¸zª½¸zÀù©Î(©M)¨ÅÀù. ¹w©w©Û¦¬26¦ì. ¤£ª¾¹D26¦ì¬O§_¤À°t¬°毎¤@ºØÀù¯g6-7¦ì? ©Î¬O«ç»ò¤À°tªk? OBI-822/821¬I¥´©ó¨ÅÀù©M§Z±_Àù¨ü¸Õ¯f±wªº¾¯¶q¬°OBI-822 (equivalent to 30 £gg of Globo H) and OBI-821 (100 £gg) ¤½¥qÀ³¸Ó¤w¸gª¾¹D¦b¨C¤@¦ì±wªÌªº§K¬Ì¤ÏÀ³, ²£¥Í¦h¤ÖGlobo H, SSEA-3, SSEA-4ªº IgG©M IgM§ÜÅé¶q. OBI-833/821¤@´Á¸ÕÅ窺¾¯¶q, OBI-821¤´µM¥Î100 £gg, OBI-833¦³¤TºØ: 10 £gg, 30 £gg, 100 £gg, Á`¦@¬I¥´10°w. ¥Dn¥Øªº¬°¸ÕÅçÃÄ«~ªº¾¯¶q¼W±j¹ï¨ü¸Õ¯f±wªº¦w¥þ©Ê©M@¨ü©Ê. ¦¸n¥Øªº¬°¸ÕÅç¥|ºØÂಾ©ÊÀù¯g±wªÌªº§K¬Ì¤ÏÀ³, ²£¥Í¦h¤ÖGlobo H, SSEA3, SSEA4ªº IgG©M IgM§ÜÅé¶q. ¬°¤°»ò¿ïªÍÀù, GÀù, ¤j¸zª½¸zÀù©M¨ÅÀù, ¦Ó¨S¦³¯Ø¸¢Àù? °£¤F¤§«e¥xÁÞ¤j»¡ªº"¥«³õ¾É¦V - ¤jÃÄ", ¿ï¨ÅÀùªº¥Dnì¦], À³¸Ó¬O¬°¤F©MOBI-822/821°µ¤ñ¸û. ¤¤¬ã°|ªº¤p¹«¸ÕÅç, Globo H-KLH/QS21, Globo H-DT/C34, Globo H-DT/QS21²£¥ÍªºGlobo H, SSEA3, SSEA4ªº IgG©M IgM§ÜÅé¶q, ±qFig.3©MFig.5¥i¥H¬Ý¥X, Globo H-DT/QS21²£¥Íªº IgG©M IgM§ÜÅé¶q³£¬O¬Û¹ï¤Ö¶q, ¤×¨ä¬OSSEA4ªº IgG¯S§O¤Ö. ¯E¹©ªº¬ãµo¤HûÀ³¸Óª¾¹D³o¨Ç¸ê®Æ, ¦Ó¥B¦Û¤vÀ³¸Ó¤]°µ¹L¦P¼Ëªº¸ÕÅç, ¬°¦ó¤£¿ïGlobo H-DT/C34, «o¥ÎGlobo H-DT/QS21? ¥LÌÀ³¸Ó¦³¤£±o¤£¥Îªºì¦], ¥u¬O§Ṳ́£ª¾¹Dì¦]¦Óı±o°g´b. ©Ò¥HGlobo H-DT/QS21ªº¤@´Án¿ï¨ÅÀù, ¤~¯à©MGlobo H-KLH/QS21¦b¤HÅ骺§K¬Ì¤ÏÀ³©M²£¥Íªº IgG IgM§ÜÅé¶q°µ¤ñ¸û. µ¥¤@´Áµ²ªG¥X¨Ó, ¦pªG¤@¤Á¦p¹w´Áªº²z·Q, «h«öpµeÄ~Äò°µ¤G/¤T´Á; ¦pªG¤£¦p¹w´Á, ¤½¥qÀ³¸Ó¦³¦]À³ªº¤èªk. ¾P°âÅv§Qª÷¤w¸gq©w¤F, OBI-822/821Á`¦@¬°8%, ¥Iµ¹SKI, Cubist©M¤¤¬ã°|; OBI-833¬°2.5%, ¥u¥Iµ¹¤¤¬ã°|. ¤WÂd«eªº¤½¶}»¡©ú®Ñ, ¤@¦ìLady¯Î«ùªÑ1933±i, ¤@¦ìLady£«ùªÑ3000±i(¤ñ¦oªº¥ý¥Í2302±iÁÙ¦h). |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/12/28 ¤W¤È 10:25:27²Ä 104 ½g¦^À³
|
¥Ñ²Ä¤@°]¸g¶g¥Z¡A±çºÑÁø±M³X±i¸³ªº¤å³¹¤¤ ¤p§Ì»{¬°¥H¤U³o¥y¸Ü¬OÃöÁä ¡uOBI833 ¸Ñ¨M¡u¸ü¨ã¡v³Q¥@¬É¤j¼tÃbÂ_ªºÃøÃD¡A ¼í¶®¥Í§Þ¸Ñ¨M¥¼¨ÓOBI822 ªº¥Í²£¤jÃøÃD¡C§Ú¬Ý¨ìªº¯E¹©¡A¥L¤w¸g¦b°µ®³¨ìÃÄÃÒ¤§«áªº©Ò¦³·Ç³Æ¡I¡v 1.833ªº¸ü¨ã±N¥Ñ¦åÂųJ¥Õ§ï¬°¥Õ³ï±ìµß¡G ³o«D±`ªº«n¡A ¸Õ·Q¡A¸U¤@822¡B833«D±`¦¨¥\¡A¹ï¤èn¦]¸ü¨ã¹ï§ÚÌ·à¤l¤j¶}¤f¡A¨º¤]¬O¤@¥ó¶Ë¸£µ¬ªº°ÝÃD 2.822¥æ¥Ñ¼í¶®¡GÁo©ú¡A¤p§Ì¤£¦AÂØz 3.¯E¹©¤w¦b¶i¦æ©Ò¦³¤§«áªº·Ç³Æ¡AÆg¡I |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/12/28 ¤W¤È 09:25:20²Ä 103 ½g¦^À³
|
¥xÁÞ¤j ·PÁ±zªº´£ÂI¡A¤p§Ì«ä¦Ò¤@©]¡AT¶ë¹y¶}¡A«¢«¢«¢,ÀY¾v¤S¥Õ¤F¤£¤Ö 1.833²Ä¤@´Á¥Î¤jÃĨӴú¸Õ¡A²Ä¤G¡B¤T´Á½T¹ê¥i¥HÁ{§É¨ä¥¦ºØ¯f¯g ¦ý»¡©ú®Ñ¤¤ªº¯ØŦÀùÀ³¸Ó¬O¸ê®Æ¡A¦ýµL¨¾ 2.12¤ë26¤éªº»¡©ú®Ñ¡A½T¹ê¦³¨Ç¸ê®Æ ¨Ò¦p¡A¦¹¦¸¤½¥q¤w¤½§in¶Ò62»õ¡A¦ý¸ê®ÆÁÙ°±¯d¦b40»õ ÁÙ¦³´£¨ì822n©e°U¥N¤u¼t¡A¦ý®Ú¾Ú10¤ë¥÷ªº²Ä¤@°]¸g¶g¥Z¡A±i¸³ªº±M³X ¬On¥æµ¹¼í¶® 3.±q·s¡B¸ê®Æ¨Ó§PÂ_¡A¤½¥qªº¬Fµ¦¤£Â_ªº°µ×¥¿¡A×¥¿ªº¥Øªº»P¥Ø¼Ð¡A ¬O....¤½¥q¤w´x´¤¼Æ¾Ú¡A¦Ó¥B¥Ø«e¡u¤@¤Á¶i®i¤Q¤À¶¶§Q¡v¡]³o¥y¸Ü¬O»¡©ú®Ñ¤¤»¡ªº¡^ 4.¥xÁÞ¤j»¡ªº¦n¡A¤@¦¸4ºØ¤jÃÄ¡A¯uªº¬O¶¯¤ß§§§Ó¡B©ñ²´¥þ¤HÃþ ¯E¹©¥[ªo |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/12/27 ¤U¤È 10:49:33²Ä 102 ½g¦^À³
|
¥xÁÞ¤j ·PÁ±zªº»¡©ú ¤p§Ì¤F¸Ñ±zªº·N«ä ¦ýÁÙ¬O¦³ÂIºÃ°Ý¡A¤p§Ì¥Ø«eÁÙµLªkÂç²M¦Û¤vªººÃ°Ý Ä´¦p¡A³o4ºØÀù¯g¤¤¡AªÍÀù¡B¤j¸zÀù¡BGÀù¬O¤@¼Ëªº ¦ý²Ä4ºØ¨ì©³¬O¨ÅÀù©Î¯ØŦÀù ©Î¥¼¨Ó¥xÆW833·|±q¯ØŦÀù²Ä¤G´Á¶}©lÁ{§É¡H ¡]¦p¦P§Z±_Àù¤@¼Ë¡^ §Úª¾¹D¬ü°ê²Ä¤@´Á³q±`¬O¦w¥þ©Ê´ú¸Õ ¦ý¬ü°ê²Ä¤G´ÁÀ³¸Ó¤£·|¶]¥X¤@ӲĤ@´Á¨S¦³¸g¹LÁ{§Éªº§a¡H¡I Åý§Ú¦A«ä¦Ò«ä¦Ò..... ©Î³\§Ú¸£³U¥´µ²¡A¦ý³oÓµ²¥d¦bþ §Ú¦A·Q¤@¤U ·PÁ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/12/27 ¤U¤È 09:28:39²Ä 101 ½g¦^À³
|
Faith ¤j 12¤ë26¤é¤WÂd»¡©ú®ÑÁ{§É¤@´Á¸ÕÅç¡A°w¹ïªÍÀù¡B¤j¸zÀù¡BGÀù¡B¯ØŦÀùµ¥¯f¤H¶i¦æÃĪ«¦w¥þ©Ê¤ÎÃĮĵû¦ô, 12¤ëªì¤½¥qºô¯¸¤½§i: ÀÀ°w¹ïªÍÀù¡BGÀù¡B¤j¸zª½¸zÀù©M¨ÅÀù¤wÂಾ,¹ê¬IÁ{§É¤@´Á¸ÕÅç¬On½T©wÃÄ«~ªº¦w¥þ©Ê Ó¤H²z¸Ñ:Á{§É¤@´Á¸ÕÅç¬O¥H½T©w833ªº¦w¥þ©Ê,¥un833¦w¥þ©Ê¨S°ÝÃD, ¥¼¨Ó¹ê»Ún°µ¨º¤@ºØ¾AÀ³¯g³£¥i¥H,¥H«e822¦b¬ü°êMSKCC ¹ê¬I¤@´ÁÁ{§É®É¥u°µ¨ÅÀù»PÄáÅ@¸¢Àù,¨S¦³°µ§Z±_Àù,·í¥xÆWp¹ºn°µ822§Z±_Àù®É¤£¥²±q¤@´Á°µ, ª½±µ¸õ¯Å´Á±q¤G´Á¶}©l,·í833¤@´ÁÁ{§É¦w¥þ©Ê¨S°ÝÃD,¥¼¨Ó833¤]¥i°µ¨ä¥L¤Q´XºØÀù¯gªº¤G´ÁÁ{§É,¯E¹©¤@¤U°µ¥|ºØÀù¯gÀ³¬On·j¶°Á{§É¼Æ¾Ú,¬°¥¼¨ÓÁ{§É¸ÕÅ窺¦¨¥\°µ¦n¸U¥þ·Ç³Æ,¦]¬°ªÍÀù¡B¤j¸zª½¸zÀù ¨ÅÀù¬O¤jÃÄ,¨Ï¥Î¤H¤f²³¦h,¯E¹©¤@¤U¶}¥X¤T¿´¯è¥À,®ð¶Õ¶¯°¶ ¥H¤W¬OÓ¤H¸ÑŪ ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/12/27 ¤U¤È 08:29:21²Ä 100 ½g¦^À³
|
¦U¦ì¤j¤j ¤p§Ì±N»¡©ú®Ñªì¨B½¾\«á¡A·Q»P¤j®a°Q½× ¤p§Ì»{¬°»¡©ú®Ñ¤¤¦³·s¡B¸ê®Æ «e±´X¶¤@©w¬O·sªº ¦ý¹ï©ó833°µ¯ØŦÀù ¤p§Ì»{¬°¬O¤@Ӱݸ¹(¤p§Ì»{¬°³o¬O¸ê®Æ) ¦]¬°¤½¥qºô¯¸12¤ë3¤é¤½§Gªº4ºØÀù¯g¨Ã¤£¥]§t¯ØŦÀù ¥B4ºØ¬O¤w³q¹L¬ü°êFDAªº¥Ó½Ð ^¤å¤¤¤]¬O³o4ºØ ¦U¦ìı±o©O¡H ¤£ª¾¦³þ¦ì¤j¤j¥i¥HÀ°¦£»¡©ú©Î½Ð±Ð¤½¥q ·P®¦ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2014/12/27 ¤W¤È 08:20:59²Ä 99 ½g¦^À³
|
Cliff¤j ÁÙ¬O±o¾a±z©Î¤j®a¤F! ¤p§Ìµ{«×¦³ «Ü¦h¦a¤è¦³Åª¨S¦³À´ «Ü·Q§Ë²M·¡ÃöÁä «o¤ß¾l¤O²Ò ¦ý¤´·|Ä~Äò§V¤O ÁÂÁ±z ´Á«Ý±z¤Î¤j®aªº«ü¾É! |
|
|
·|û¡GJM10139061 µoªí®É¶¡:2014/12/27 ¤W¤È 12:06:58²Ä 98 ½g¦^À³
|
Thanks. ¯E¹©¹q¤l¸ê®Æ¬d¸ß§@·~ http://doc.twse.com.tw/server-java/t57sb01?step=1&colorchg=1&co_id=4174&year=&seamon=&mtype=B& |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/12/26 ¤U¤È 11:19:29²Ä 97 ½g¦^À³
|
OBI-833¡G ¾AÀ³¯g³Wµe¤´¬O¯ØŦÀù. ¨Ï¥Î¡u·s¿oªº¤Æ¾ÇÁäµ²ªk¨ÓÁpµ²ÁÞ§Üì(Globo H) »P¸üÅé³J¥Õ( ¥Õ³ïÃþ¬r¯À¡ADT-CRM197)¡v¡A§Q¥ÎOBI ¤º³¡¬ÛÃö§Þ³N¡A½T»{¨âªÌ³Ì¨Î¤ñ¨Ò¡A¥H¹F¨ì´£¤É¤HÅé§K¬Ì¨t²Î¹ïÁÞ§Ü쪺¿ëÃѯà¤O¡A±q¦Ó¹F¨ì¥D°Ê¦¡§K¬ÌªvÀøªº¥Øªº¡C ¬Ý¨Ó²{¹êª©¡GGH5.1-DT/QS-21©Î¬O»»·Qª©¡GGH5.1-F-DT/QS-21¡BGH5.1-N3-DT/QS-21¤£¬O¤£¥i¯à¡C ÁÙ¦³«Ü¦h»P¹ï¤âªº¤ñ¸û¡A¦³±oŪ¤F¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/12/26 ¤U¤È 11:02:49²Ä 96 ½g¦^À³
|
·s¸ê®Æ¤Wºô¤F 103¦~12¤ë²{ª÷¼W¸ê¤½¶}»¡©ú®Ñ½Z¥»(»ù®æ¼È©wª©) ¦b¤½¶}¸ê°TÆ[´ú¯¸¡X¹q¤l®Ñ 402¶ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/12/8 ¤U¤È 07:22:04²Ä 95 ½g¦^À³
|
Cliff¤j ¼·¤j D§b¤j ¤p©_¤j ÂŤѤj ¦U¦ì¤j¤j : ÁÂÁ§AÌ´£¨ÑªºÄ_¶Q¸ê°T |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/12/8 ¤U¤È 06:30:44²Ä 94 ½g¦^À³
|
¦³¤Hª¾¹D833¤@´Á¬O¦b¥xÆW°µÁ{§É©Î¬O¦b¬ü°ê°µÁ{§É,¦¬26¤H¬O¨CºØÀù¯g¦¬26¤H ©Î¬O¥þ³¡¦¬26¤H |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/12/8 ¤U¤È 01:51:39²Ä 93 ½g¦^À³
|
Cliff¤j ·PÁ ª½±µ¡B¥¿½T Æg |
|
|
·|û¡G´µ¤p¤å10139040 µoªí®É¶¡:2014/12/8 ¤U¤È 01:48:18²Ä 92 ½g¦^À³
|
£«¬Â¤jÁ¿ªº¸ò§Ú¤º¤ßªº·Qªk¤£¿Ñ¦Ó¦X, ³o¬O¤@Ó¤d¸üÃø³{, ¸ê²£¿¼W, ¤@Ó¦¤é¹F¨ì°]´I¦Û¥Ñªºµ´¨Î¾÷·|, ¬G§Ú¶¢¸m¸êª÷¤w¥H1:1ªº¤ñ¨Ò«ùªÑ¤¤¸Î»P¯E¹©º¡ÀÉ |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2014/12/8 ¤U¤È 01:18:52²Ä 91 ½g¦^À³
|
¦pªG20¦~«e¶RÂE®ü©ñ¨ì²{¦bÁÈ135¿,¶R¥x¿n¹qÁÈ35¿.²{¦bn§ä¥¼¨ÓÃþ¦ü¦¨ªøªÑ,§Ú·Q¥u¦³¥Í§ÞªÑ.¯E¹©.ÃĵØ.¤¤¸Î³£¦³§Æ±æ,¤£n¦b¥Gµu½u½L¾ã.¤@½ú¤l¤]¨S´X¦¸¾÷·|.¤×¨ä¯E¹© |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/12/8 ¤W¤È 11:52:28²Ä 90 ½g¦^À³
|
¤£¥²¦A²q,°Ý¨ì¤F¡C ´CÅé³ø¾É´£¨ì¨º¥|ºØÀù¯g¬O833¤@´Án¦¬®×¹ï¶H¡A¥H«K§Q¦¬¨ì®×¬°¦Ò¶q¡C¦Ó¤@´Á¸ÕÅç¥u¬On½T©w833ªºÃĪ«¦w¥þ©Ê»P°Æ§@¥Î¡A¥¼¨Ó833ªº¾AÀ³¯g¹ï¶H¤£¤@©w¬O³o¥|ºØ¡A·íµM¤]¥i¯à¬O¡C ©Ò¥H¸ò¤WÂd»¡©ú®Ñ©Ò¨¥¨S¬»Ä²¡F¸ò´CÅé¤é«e³ø¾É¤]¨S½Ä¬ð¡A¥u¬O°OªÌ¨S·dÀ´¤]¦]¦¹¨S»¡²M·¡¡C ¨ÅÀù¤£¨£±o¬O¥¼¨Ó833ªºªvÀø¹ï¶H¡C ÁÙ¦³Clinicaltrial.gov¬°¦ó©|µL833¸ê®Æµn¿ý¡H ¹ï¤è»¡·|¤ÏÀ³¤W¥h¡C |
|
|
·|û¡G¶Wô10139528 µoªí®É¶¡:2014/12/8 ¤W¤È 11:51:35²Ä 89 ½g¦^À³
|
¤µ¤Ñ¤WÂdªº¥Í§Þ¤S«ùÄò¤jº¦¡A´¼Àº±q쥻¸¨«á¯Eô200¤¸¡A°l¨ì³Ñ¤U¤£¨ì100¤¸¡A³o¼Ë¤Ï¦Ó¹ïÄY«§C¦ôªº¯Eô§óÅ㪺¤£¦X²z¡AÁo©úªº¤H¡An¿ï¾Ü¥h°l¤W¥«Âd³Ð°ªªº¥Í§ÞªÑ¶Ü¡HÁÙ¬OÀqÀq§G§½ÄY«§C¦ôªº¯E¹©©O¡H |
|
|
·|û¡GÂŤÑ10138178 µoªí®É¶¡:2014/12/8 ¤W¤È 11:27:03²Ä 88 ½g¦^À³
|
·PÁµ½¤H¤j Cliff¤j Faith¤j ¥xÁÞ¤jªº¸Ñ»¡ ¦Ó¥BOBI-833ªº¤u§Ç©M¦¨¥» À³¸Ó¤]·|°§C«Ü¦h. OBI-833¥i¥H¤Þ°_§ó±j¯Pªº§K¬Ì¤ÏÀ³¨Ã³q¹LÁ{§É«eªº°Êª«¸ÕÅç ¥i¨£°Êª«ÁÙ©Ó¨ü±o°_¸ÕÅç ¬G±À·Q¤HÅéÀ³¸Ó¤]¬O©Ó¨ü±o°_ ¥u¬O¾á¤ß¤ñ822±j¯Pªº¤ÏÀ³ °Æ§@¥Î·|±j¨ì¤°»ò¼Ëªºµ{«×? ³o¬O¥H«án«ùÄòÆ[¹îªº. |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2014/12/8 ¤W¤È 09:21:24²Ä 87 ½g¦^À³
|
Cliff¤j¡G ÁÂÁ±zªº¸Ñ»¡¡I |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/12/8 ¤W¤È 09:16:09²Ä 86 ½g¦^À³
|
¥xÁÞ¤j ·PÁÂ Æg |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/12/8 ¤W¤È 09:02:10²Ä 85 ½g¦^À³
|
¬O¥H¥½´ÁªÍÀùGÀù¤j¸zÀù»P¨ÅÀù¬°¾AÀ³¯g ¯E¹©ºô¯¸¤w¦b¤T¤é¤½§i |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/12/8 ¤W¤È 08:29:02²Ä 84 ½g¦^À³
|
Cliff¤j.ÂŤѤj.µ½¤H¤j §Úªì¨B§PÂ_¬O°OªÌ¼g¿ù §Ú°O±o ¤WÂd»¡©ú®Ñ¤¤´£¨ìªº,»P°OªÌ¼gªº¤£¦P ¥B833¦³¥i¯à¥H©t¨àÃÄ(³oÂI§Ú¦A¨Ó¬d¤@¤U)ªº¤è¦¡§¹¦¨Á{§É¹êÅç ·m¥ý¤W¥« ¥H¤WY¦³»~½Ð«ü¥¿,·PÁ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/12/8 ¤W¤È 01:03:07²Ä 83 ½g¦^À³
|
ÂŤѤj¡Bµ½¤H¤j¡G ¦P¤@¥ó·s»D¡Aª÷´I±Úºôªº³ø¾É²§©ó¨ä¥L¦h®a´CÅé³ø¾É¡G¡]http://www.e-rich.com.tw/cgi-bin/big5/k/374c?q1=dp1&time=09:56:02&q27=374c&q65=8868898&q7=&q22=20141202095546¡^ ¡u¡K¡K¥DnÂê©w¯ØŦÀù¡BGÀù¡B¤j¸zÀù¤ÎªÍÀùµ¥¡C¡K¡K¡v¡F ¤j¦h¼Æªº³ø¾É³£´£¨ì¨ÅÀù¡A¦Ó¥B¹wp¦Ü2016¦~²Ä¤G©u§¹¦¨¦¬®×¡K¡K¡F¦Ó¤WÂd»¡©ú®Ñ¤W¬O°w¹ïªÍÀù¡B¤j¸zÀù¡BGÀù¡B¯ØŦÀù¡A³W¹º104¦~¦Ü105¦~²Ä¤G©u§¹¦¨Á{§É¤@´Á¸ÕÅç¡A¡C·|¤£·|¤S¬O°OªÌ§Ë¿ù¡H |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/12/8 ¤W¤È 12:48:17²Ä 82 ½g¦^À³
|
¤p©_¤j¡G ·|¤£·|¬O©ñ¤J¤j¸zª½¸zÀù¼Ð¹vÃĪ«¡uº¸¥²±oµÎ¡vErbitux©Î¡uÀù«ä°±¡v¡]Avastin¡^¡H¦]¬°¥¦Ì³£¬O³æ®è§ÜÅé¡A±z¤j·§¸ò§Ú¤@¼Ë¡Aª½Ä±¦a¥ý·Q¨ì¬O±q¨ä¥L±wªÌ¨¤W´£¨ú¥X¨Óªº§ÜÅé¡K¡K¡A§Ú·QÀ³¸Ó¬O³æ®è§ÜÅ骺¾÷·|¤j¨Ç¡A¤è«K¤S¹ê»Ú¡C ¡uº¸¥²±oµÎ¡v¬OÂಾ©Ê¤j¸zª½¸zÀùªvÀøªº·sªZ¾¹¡A¥¦¬O¤@ºØ³æ®è§ÜÅé¡A¤]¬O¤W¥Ö¥Íªø¦]¤l±µ¨ü¾¹¡]EGFR¡^ªºªýÂ_¾¯¡C¡v¡]http://www.tmn.idv.tw/tcfund/medecine/nm_37_1.htm¡^ ¡uÀù«ä°±¬O¤@ºØ§í¨îÀù²ÓM¦åºÞ·s¥Íªº³æ®è§ÜÅéÃĪ«¡A¥i¥H©M¦åºÞ¤º¥Ö¥Íªø¦]¤lµ²¦X¡A§í¨îÀù²ÓMªº¦åºÞ·s¥Í¡A¹F¨ì§í¨îÀù²ÓM¥Íªøªº¥Øªº¡C¡v¡]http://www.twhealth.org.tw/index.php?option=com_zoo&task=item&item_id=157&Itemid=21 ¡^ ÁÙ¦³§Úı±o¥i¥H¨C¦¸©ñ¤J¤£¦Pªº§ÜÅé¡A¨Ó¹F¨ì¼´¨ú¬Û¹ïÀ³ªºÀù²ÓM¡C¦pªG©ñ¤Janti-GH Ab¡]anti-SSEA-3 Ab¡Banti-SSEA-4 Ab¡^¡A¦³¾÷·|¥i¥H¼´¥X¨º16ºØ¤W¥ÖÀùªº²ÓM¡C´N¬Ý¥¦ªº¦¨¥»¡B±Ó·P«×¡B¥i§_¶q²£¡BÀË´úªá¶O®É¶¡¡B¥i§_¦P®É©ñ¦hºØ¤£¦P§ÜÅéµ¥¦]¯À¨Ó¨M©w¦³¨S¦³°Ó·~»ùÈ¡C Ó¤Hı±o¡u±q±wªÌ¨¤W¨ú±o¤j¸zª½¸zÀùÀù²ÓMªº§ÜÅé¡v¤£¤Ó®e©ö¡A©Î³\¤w¦³§Ú©Ò¤£ª¾ªº·s§Þ³N»P§@ªk¤]»¡¤£©w¡C ½Õ¤£¨ìì¤å¡A¤]¨S§ä¨ìªø©°µoªí¬ÛÃö¸ÕÅ窺µ²ªG¡A©Ò¥H¤£©ö§PÂ_¡C |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2014/12/8 ¤W¤È 12:25:18²Ä 81 ½g¦^À³
|
ÂŤѤj, OBI-833¤]n°µ¥½´Á¨ÅÀùªºÁ{§É¸ÕÅç, §Úªº¬Ýªk: 1. OBI-822ªº±M§Q´Á©M±ÂÅv´Á³£¤ñOBI-833¦¨ì´Á. 2. 833ªºÀø®Ä¦pªG¤ñ822¦n«Ü¦h, ¤£¶È¥i¥H±µÄò822ªº¥«³õ, ÁÙ¥i¥HÂX®i¥«³õ. 3. 822ªº¾P°âÅv§Qª÷Á`¦@8%, ¥Iµ¹SKI, Cubist©M¤¤¬ã°|. 833ªº¾P°âÅv§Qª÷¥u¦³2.5%, ¥Iµ¹¤¤¬ã°|. °²³]¾P°âÃB¬O¥x¹ô100»õ¤¸, ¥i¥H¤Ö¥I¾P°âÅv§Qª÷¥x¹ô5.5»õ¤¸, ¤ÏÀ³¦bEPS¤W¦³3¤¸¦h, ¤]·|¤ÏÀ³¦bªÑ»ù¤W±. |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2014/12/7 ¤U¤È 11:21:42²Ä 80 ½g¦^À³
|
Cliff¤j¡A ½Ð±Ð±z¤@Ó°ÝÃD¡A ¡yÀù²ÓM®·¤â¡z¤¤´£¨ì¡G ¡y³oÓ©`¦Ì¶î®Æ¸Ì±¡A¨ä¹ê¥[¤J¤F¬YºØÀù²ÓMªº§ÜÅé¡A¥i¥H±M¤@©Êªº¿ëÃÑÀù²ÓM¡K¡A ¦b¹ê»ÚªºÀËÅéÅçÃÒ¬O±Ä¥Î¤j¸zª½¸zÀù¯f¤Hªº¦å²G¡A ½Ð°Ý¡G 1.³oÓ¹êÅ窺¡y¬YºØÀù²ÓMªº§ÜÅé¡z¬O«ü¥²¶·¬O¤j¸zª½¸zÀùÀù²ÓMªº§ÜÅé¶Ü¡H©ÎªÌ¥LºØÀù¯gªºÀù²ÓMªº§ÜÅé¤]¦æ©O¡H 2. °²¦p¡y¬YºØÀù²ÓMªº§ÜÅé¡z¦b¦¹¹êÅç¨Ò¤l¤¤«üªº¬O¤j¸zª½¸zÀùÀù²ÓMªº§ÜÅé¡A¨º³o¤j¸zª½¸zÀùÀù²ÓMªº§ÜÅé®e©ö¨ú±o¶Ü¡H¬O±q¤HÅ餤¨ú±o©ÎªÌ¤Æ¾Ç¦X¦¨§Y¥i¡A¦¨¥»·|«Ü°ª¶Ü¡H |
|
|
·|û¡GÂŤÑ10138178 µoªí®É¶¡:2014/12/7 ¤U¤È 09:21:38²Ä 79 ½g¦^À³
|
¤p§Ì·Q½Ð±Ð¤j¤jÌ: 1.OBI-833Á{§É¤@´Á¸ÕÅç¹ï¶H¬° ªÍ.G.¸z.¨Å ¥|ºØ¤w²¾Âà ²{¦æÀøªk¤´µLªkªv¡ªº¯f±w ´Á¤¤¨ÅÀùªº¹ï¶H ¤£´N©MOBI-822«Å|¤F¶Ü? Y¬O¥H«áÃĪ«¦¨¥\¤W¥« ¤£´N¦Û¤v¥´¦Û¤v? 2.OBI-833¥i¥H²£¥Í§ó±j§óªøªº§K¬Ì¤ÏÀ³ ¨º¬O§_¹ï©óOBI-822³¡¤À¨S¦³¤ÏÀ³©Î¤ÏÀ³«Ü®zªº¹ï¶H ¤]¬O¦³®Ä©O?(³oÓ¥i¯ànµ¥¤@´Á¸ÕÅç µ²ªG¤~·|ª¾¹D) |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/12/7 ¤W¤È 11:09:39²Ä 78 ½g¦^À³
|
¡uÀù²ÓM®·¤â¡v¦¨¥\§ÞÂà¡G (http://www.genomics.sinica.edu.tw/index.php/tw/news/lastest-news/438-2014-11-14-03-46-45 ) ¶È¸`¿ý³¡¤À©ó¤U¡A½Ð´`¸ô®|¦Üì¥X³B§ó²M·¡¡C ¡u¶}µo¥X¤@®M±q¦å²GÀË´úÀù²ÓMªº¤èªk»P»ö¾¹¡F³oÓ§Þ³N¥i¥H±q¼Æ¤Q»õªº¦å²y²ÓM¸Ì¡A¼´¥X¦b¨ä¤¤·L¥G¨ä·L¡B¥HӼƳæ¦ìpªºÀù²ÓM¡C¡v ¡u¦å²G¼Ë¥»¤¤¤Q¤Àµ}¤Öªº¸~½F²ÓM(circulating tumor cells, CTC)¬O¬ì¾Ç®a±´°QÀù²ÓMÂಾ©Î¬O¹w´úÀù¯gªº¤@Ó½ÒÃD¡CÂå¥Í̧ó«æ¤Áªº§Æ±æª¾¹D¡A¦bÀù²ÓM¤Á°£ªº¤â³N¡B¤ÆÀø«á¡A¥Î²´«eªºÀË´úªk³£¬Ý¤£¥X¦³¥ô¦ó³Ñ¾lªºÀù²ÓM®É¡A¦p¦ó¯à½T«O¤w¸g®Ú°£¤F¡H¡v ¡u¹ê»ÚªºÀËÅéÅçÃÒ¡A¬O©Mªø©°Âå°|ªº¹Î¶¤¦X§@¡C¥L̤@¦@ÀË´ú¤F¤@¦Ê¤C¤QÓ¤j¸zª½¸zÀù¯f¤Hªº¦å²G¡Aµ²ªGµo²{¡A¹ê»ÚÀË´ú¨ìªºÀù²ÓMªº¼Æ¶q¡A©MÀù¯g¯f¤HªºÄY«´Á§O¡A§¹¥þ¬O¥¿¦VªºÃöÁp¡C §óÅý¤H¦YÅ媺¬O¡A¤@¯ë»{¬°¡A¹s´Á¡B¤@´Áªº±wªÌÅ餺ªº¸~½FÀ³¸Ó¶°¤¤¦bìÂI¡AÁÙ¨S¦³ÂX´²¡F¦ý¬O¡A¬ã¨s³ø§i«ü¥X¡A¨ä¹ê¡A¦b³oӮɴÁ®×¨ÒÅã¥Ü¡A¤w¸g¦³¦Ê¤À¤§¤T¤Q¤ªº±wªÌªº¦å²G¤º¡A¤w¸g¦³·È¥X¨ÓªºÀù²ÓM¤F¡C¡v ¦X«×¥Íª«ºë±K¥Íª«¬ì§Þ¦³¤½¥q¡G¤w¶i¾n¤¤¬ã°|°ò¦]Åé¬ã¨s¤¤¤ßªþ³]¥Í§Þ¨|¦¨¤¤¤ß http://www.incubator.sinica.edu.tw/index.php?option=com_content&view=category&id=46&Itemid=69&lang=zh CellMax Life is revolutionizing early cancer detection and prevention, bringing a superior quality of life to all. With its simple, accurate, and proprietary blood test, CellMax¡¦s goal is to screen every person in the world. The technology was developed by scientists from Stanford University at Academia Sinica¡¦s Genomics Research Center in Taiwan. CellMax has offices in Silicon Valley (U.S.) and Taiwan and is funded and backed by a leading venture capital firm in the U.S. and prominent technology industrialists in Taiwan. ¥¼¨Ó»POBI-868¬OÄvª§¬O¦X§@¡A½Ð¦Û¦æ¸ÑŪ¡C |
|
|
·|û¡G¤p¤p§ë¸ê¤H10138368 µoªí®É¶¡:2014/11/12 ¤U¤È 05:38:35²Ä 77 ½g¦^À³
|
Cliff¤j¡A ¯u¬O¤Ó·PÁ±zªº¸É¥R¤F¡I ·P®¦·P®¦¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/11/12 ¤W¤È 09:42:34²Ä 76 ½g¦^À³
|
Cliff¤j ÆgÆgÆg ¥i±¤§Ú¤£·|¥´ªo¸Ö,¤£µM¤@©w¤]¨Ó¤@½gºÙÆg±zªº!(«¢«¢«¢) S¤k¤h¦³·s°ÊºA ¤j®an°O±o°lÂÜ³á ¤@°_¥[ªo |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2014/11/12 ¤W¤È 09:17:51²Ä 75 ½g¦^À³
|
Cliff¤j¡Aµ½¤H¤j¡A «¢«¢¡I |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2014/11/12 ¤W¤È 06:08:11²Ä 74 ½g¦^À³
|
¯E¤Í©ú¹î¬}¾÷¥ý¡AÀR«Ý©ú¦~§âÁç±È¡A¦W´¥|®ü¤£·sÂA¡AѻŽ½N²´Áɯ«¥P¡C Cliff¤j, ¯uªº«D±`¨ØªA±z, ¤£¥u¹ï¥Í§Þ²£·~ÁAY«ü´x, §u¸Ö¤S¥X¯«¤J¤Æ. ©ú¦~¸Ñª¼¤½§G¦¨ªG, ²³¯E¤Íªº¤ß¹Ò©Mªí±¡´N¬O"ѻŽ½N²´Áɯ«¥P", ¯E¤ÍÌn¶}©l¯dÄGŽ, ©ú¦~¤~¯à"ѻŽ½N²´Áɯ«¥P"!!! ¤£¬O¾Ç¦WÃĤ£¦n, ¦Ó¬OÄvª§ªÌ²³, §Q¼í·LÁ¡, ¿E¤£¤F¬üÄRªº®öªá, ´¤£¦¨ÀéÄꪺ±mi. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/11/12 ¤W¤È 02:44:35²Ä 73 ½g¦^À³
|
³o´XºØ³£¬O¦ÑKKªºÃĤF¡A¸ò822¬O¥þ·s¦¨¤À¦³«Ü¤jªº®t§O¡AÁöµM¤]ºâ¬O®³·sÃÄÃÒ¡C Ä_ÄÖ¨º¤@´ÚÄY®æ¨Ó»¡¬O¦ÑÃÄ·s¥Î¡A¯u¥¿ªº¡u·sÃÄ¡v¡A¤¤¸ÎªºTMB-355¡]ÀR¯ß«¬¡^¦³¾÷·|©ÞÀYÄw¡C ER¬O½wÄÀ«¬¡Aºâ¬O§ïÅܾ¯«¬¡C¨º¤ºØÃÄùØ¡AÁÙÄÝ©ó¬OER«¬ªº¾Ç¦WÃÄ¡C Amrix¡GFDA 2007/2/1³q¹L¡]https://www.centerwatch.com/drug-information/fda-approved-drugs/drug/1032/amrix-cyclobenzaprine-hydrochloride-extended-release ¡^¡A Aricept ¡GFDA1996¦~®Öã¥Î©ó»´¦Ü¤¤«×¥¢´¼¯g¡C2006®Öã¥Î©ó¤¤¦Ü««×¥¢´¼¯g¡C ¡]http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108768.htm ¡^ Nifedipine¡G¶W¦Ñªºµu®Ä¦åÀ£ÃÄ¡A§Ú¤p®ÉÔ1989¦~´N¦³¤F¡C«á¨Ó¦³ER¡]90mg¡^¡BXL¡]30mg¡^¥X¨Ó¡C¥H¦â¦C¾Ç¦WÃĤj¼tTeva©ó2001/2´N®³¨ìXL¡]30mg¡^ÃÄÃÒ¡C ¡]http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle_Print&ID=1556308&highlight ¡^ ¨ä¾l¨âÓ¤]¬OÃþ¦ü±¡§Î¡A³£¬O»á¦Ñªº¾Ç¦WÃÄ¡C |
|
|
·|û¡G¤p¤p§ë¸ê¤H10138368 µoªí®É¶¡:2014/11/11 ¤U¤È 11:21:11²Ä 72 ½g¦^À³
|
¥xÁÞ¤j¡A 4180 ¦w¦¨ÃÄ °£³Ìªñ(103/10/30)³q¹LªºÃÄÃÒ¥~¡A¥iÁÙ¬O²Ä¤±iÃÄÃÒò! ¥H¤U¤±i¡õ ¾Ç¦WÃÄÃÒ¨ì¤â/°Ñ¦ÒÃĦWºÙ/¾AÀ³¯g 1. Cyclobenzaprine ER Capsule / AmrixR / °©Àf¦ÙÃP¦¢¾¯ (§ä¤£¨ì½T¤Á³q¹L¤é´Á) 2. Guanfacine ER Tablet / IntunivR / ª`·N¤O¯Ê³´¹L°Ê¯g (§ä¤£¨ì½T¤Á³q¹L¤é´Á) 3. Nifedipine ER tablet / ProcardiaR XL / °ª¦åÀ£¡B¤ßµ±µh (2014.04.07³q¹L) 4. Megestrol Acetate 125mg/ml / MegaceR ES / AIDS±wªÌªº¹½¹¯g¡B´c¯fÅé½è©Îì¦]¤£©úªºÅé«©úÅã´î»´(2014.08.28³q¹L) 5. Donepezil 23mg tablet / AriceptR 23mg / »´«×¦Ü¤¤«×ªü´þ®üÀq¤ó¯f¤§Ã¨§b(¥¢´¼)¯gª¬ (2014.10.30³q¹L) ÀR«Ý¥Í§Þ¦n¤½¥qªºµoªÞ & §§¤j! Æg!! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/11/11 ¤U¤È 11:09:22²Ä 71 ½g¦^À³
|
¦U¦ì¤j¤j: 1 ¥h¦~¦X¸ê¿³«Øªº¼í¶®¥Í§Þ¬OP3µ¥¯Å³J¥Õ½èÃļt¡A¹ï¥Í²£³W®æªº°ª«×n¨D¡A¦Pµ¥¯Åªº¼t©Ð¥Ø«e¦b¥þ²yÁÙ¤£¨ì10®a¡C¸ÓP3¼t¥¼¨Ó°£¤F¥Í²£¦×¬r±ìµß¯ÀÃĪ«¡A¯E¹©ªº§ÜÀùÃĪ«¤]±N©e°U¼í¶®¥Í²£¡A¥H¥Ø«e³W¹ºªº¥Í²£³W¼Ò¡A¨¬¨Ñ¥þ²y¥«³õ©Ò»Ý 2 ¤µ¦~4¤ë»P¤¤¬ã°|ñ¸pÁÞ¤À¤l·sÃĦX¦¨§Þ³N±MÄݱÂÅv ( ·Ç³Æ±N¨Ón¤j¶q¥Í²£ÁÞ¤À¤l·sÃÄ) ¥H¤W³o2ÂI»P·sÃĬãµo¦¨¥\»P§_¬O§_¦³±K¤ÁÃö«Y? |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/11/11 ¤U¤È 09:25:17²Ä 70 ½g¦^À³
|
¥H§K¬ÌÀøªkProvengeªvÀøÄáÅ@¸¢ÀùµÛºÙªºDendreon¤½¥qÁn½Ð¯}²£«OÅ@¡C http://www.bloomberg.com/news/2014-11-10/dendreon-files-for-chapter-11-bankruptcy-protection.html ¥H±wªÌªº¦å²G¤¤¿z¥X¾ð¬ð²ÓM«á¡A¦A¥´¦^¥hÅ餺¡A§Æ±æ»¤µo¦³®Äªº§K¬Ì¤ÏÀ³§ÜÀù¡C2009¦~¤T¤ë¦]¬°¤T´Á¸ÕÅçÅã¥ÜProvenge¬Ì]¥i¥H©µªø¥½´ÁÄáÅ@¸¢Àù4Ó¤ë¹Ø©R¡AªÑ»ù¦]¦¹³æ¤é¤jº¦132.7%¡A±q7.3¬ü¤¸³°³°ÄòÄòº¦¨ì40¬ü¤¸¡A«á¦]ÃÄ»ù©ù¶Q¦¨®Ä´¶³q¡A·~ÁZ¤£®¶ªÑ»ù¤£¤ä¡A2012¦~¤T¤ë¶^¦^ì§Î6.76¬ü¤¸ªþªñ¡A2013¦~¤Q¤ë³Ñ¤U¤£¨ì3¤¸¬ü¤¸¡A¬Q¤Ñ¦¬¦b0.18¬ü¤¸¡C ©õ¡G¡uhttp://www.biotechsectorinvesting.com/2010/03/dendreon-corp-dndn-stock-price-3661.html ¡v ¤µ¡G¡uhttp://www.stoxline.com/quote.php?symbol=dndn ¡v ¥Í§Þ·sÃĤ@¦V¨ü¤HÆf¥Ø¡A ^¶¯ª¯ºµ¤@½u¶¡¡A¤WƒL¤U¬~³Ì¼õ·Î¡Aºë¬D²Ó¿ï¤ñ²´¦y¡A¦º©ê¤£©ñ³Ì¤ß°í¡C ¯E¤Í©ú¹î¬}¾÷¥ý¡AÀR«Ý©ú¦~§âÁç±È¡A¦W´¥|®ü¤£·sÂA¡AѻŽ½N²´Áɯ«¥P¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/11/10 ¤W¤È 11:56:25²Ä 69 ½g¦^À³
|
ªÀ¹Îªk¤H°ê®a¥Í§ÞÂåÀø²£·~µ¦¶i·|¤µ¤é±N·f¥¥x¡AÁ|¿ì¡u2014¨â©¤¥Í§Þ·sÃIJ£·~¦X§@½×¾Â¡v¡C¥Íµ¦·|ªí¥Ü¡A¦¹¦¸±N¦³11®a¤j³°«ÂIÃļt¡B°Ñ»P¹O30³õ¨â©¤¦X§@¬¢½Í·|¡A¬O¨â©¤ÂåÃIJ£·~¤j«¬¬¢°Ó¦X§@ªºº¨Ò¡C ±i¸³¦W¦C¨ä¤¤ ·j´M:2014¨â©¤¥Í§Þ·sÃIJ£·~¦X§@½×¾Â |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/11/9 ¤U¤È 05:57:57²Ä 68 ½g¦^À³
|
Rabbit¤j¤j¦b¤T¤Ñ«e§ä¨ìè¥XÄlªº·sªF¦è¡C¡]http://www.ncbi.nlm.nih.gov/pubmed/25371992 ¡^ ¡uImmunogenicity study of Globo H analogues with modification at the reducing or non-reducing end of the tumor antigen ¡v ¯»¶ê½×¤åùا⤣¦Pªº¦õ¾¯¡BÄâ±a³J¥Õ°µ¤ñ¸û¡A§ä¥X³Ì¨Îªº²Õ¦XGH-DT/C34¡A¤]´N¬OOBI-833¡C ³o¦^§â¸£µ¬°Ê¨ìGH¤W±¡Aª½±µ¦bGH¤W°Ê¤â¸}¡A¥[¤W¤£¦Pªº¦¨¤À°µ×¹¢¡A¥Øªº¬O§Æ±æ²£¥Í§ó±jªºIgG¤ÏÀ³¡A§â¬Ì]ªº¹Ú§ó©¹«e±À¶i¤@¨B¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/11/2 ¤U¤È 02:32:04²Ä 67 ½g¦^À³
|
¥xÁÞ¤j ±z»¡ªº¨S¿ù¡A¥xÆWªº¥Í§Þ¥¿¦bµÞªÞ¡B_§§ ¥Ø«e´N¦³¦p±i¸³¨Æ©Ò»¡¥¿¦b¼½ºØ¡BµoªÞ¶¥¬q ±i¸³¤]¤@¦A·t¥Ü822ªºÀø®Ä¤ñ¹w´Áªº¦n ©Ò¥H¦nÀ¸¦b«áÀY Åý§Ṳ́@°_ÀR«Ý¯E¹©ªº¸Ñª¼ ¥[ªo |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/11/1 ¤U¤È 11:54:30²Ä 66 ½g¦^À³
|
Faith ¤j ¥xÆW¤S¦³¤@ÁûÃijq¹LFDA ÃÄÃÒ¥Ó½Ð(¦w¦¨} ¤w¸g¦³¨âÁûÃÄ®³¨ìFDA ÃÄÃҥӽР¥Ø«eÁÙ®t¤@Áû«½S¯Åªº·sÃÄ ¥xÆW·sÃĬãµo¯à¶q¶V¨Ó¶V±j ¬ãµo³]³Æ¶V¨Ó¶V¥ý¶i ¬ã¨sªÌ¤ô·Ç¶V¨Ó¶V°ª ¤µ¤Ñ²×©ó¨£ÃѨì°ò¦]Å餤¤ßªº¤@¬y³]³Æ¡A¥u¯à¥Î¹Ä¬°Æ[¤î¨Ó¦æ®e¡A¬Û«H¦³«Ü¦h¯E¤Í¤]·|¥h°ÑÆ[ «ü¬O©¼¦¹ÁöµM¤£»{ÃÑ ¦ý»{¦P¬O¤@Pªº |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/10/31 ¤U¤È 06:07:22²Ä 65 ½g¦^À³
|
±ø¤j ²M·¡¤F ¤Ó·PÁ¤F §Aªº±À½×ȱo°Ñ¦Ò ¤p©_¤j»¡¨C¹L¤@¤Ñ ¨C¹L¤@¶g ¯E¹©ªº»ùÈ ¤£Â_¦b¼W¥[ |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2014/10/31 ¤U¤È 05:49:59²Ä 64 ½g¦^À³
|
A B C Dªí¥Ü Ó¶¥¬q¦¬®× "¹êÅç²Õ(¥ÎÃIJÕ)"¦ôpªº´_µo¤H¼Æ |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2014/10/31 ¤U¤È 05:48:26²Ä 63 ½g¦^À³
|
¥xÁÞ¤j¡A §Ú¬O¥Î¦¬®×¤H¼Æ¡A¹êÅç²Õ2/3, ¹ï·Ó²Õ1/3°µ¦¨¤Uªí¡A ¦Ó¹ï·Ó²Õ¥Î9Ó¤ë50%, 18Ó¤ë80%, 27Ó¤ë95%´_µo¾÷²v ±Àºâ¨ì2015 Q2´_µo¤H¼Æ¬ù¬°94¤H ¦Ó342¤H¤@¥b=171¤H¡A¨âªÌ¬Û®t77¤H ©Ò¥H¦pªG¹êÅç²Õ´_µo¤H¼Æ¤£¶W¹L77¤H¡A¨º´N¤£¥Î´Á¤¤¤ÀªR ¦Ó³Ì¦³¥i¯àªº±¡ªp¬O822¹êÅç²ÕªºPFS > 30Ó¤ë¡A¥B¥i¯à¦b36Ó¤ëªþªñ ¦]¬°¤@´ÁPFS¤£¶W¹L4¦~¡A®Æ·Q¤T´Á¤]¥i¯à¦p¦¹ A B C D¤À§Oªí¥Ü¦U¶¥¬q¦¬®×ªº´_µo¤H¼Æ ¹êÅç²Õ»P¹ï·Ó²Õ¨º®ÉÔ¤w¸g´_µoªº¤H¼Æ¦ôp¡G ¦¬®×®É¶¡ 2012/12 2013/6 2013/9 2014/4 2014/8 Total ¶ZÂ÷2015/Q2®É¶¡ 30(¤ë) 24(¤ë) 21(¤ë) 14(¤ë) 10(¤ë) ¹êÅç²Õ¤H¼Æ(¦ô) 66 66 20 57 19 228 ¹êÅç²Õ´_µo(¦ô) A B C D E T ¹ï·Ó²Õ¤H¼Æ(¦ô) 33 33 10 29 9 114 ¹ï·Ó²Õ´_µo(¦ô) 32 30 8 19 5 94 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/10/31 ¤U¤È 05:23:39²Ä 62 ½g¦^À³
|
±ø¤j¡G ²Ä¤»ÂI¤£¤Ó®e©öÀ´,,¤j©ó77»PPFS ªºÃö«Y¬°¦ó? A ¨ìC ¬O«ü±±¨î²ÕÁÙ¬O¥ÎÃÄ²Õ ¡A¥i§_¦A¥Õ¸Ü¤@ÂI? ÁÂÁ§A |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2014/10/31 ¤U¤È 12:58:46²Ä 61 ½g¦^À³
|
¸É¥R¤@¤U¡A ¦pªG833ªºIND¥Ó½Ðªº¬O¥Î¦b¯ØŦÀù ¨ºÀ³¸Óºâ¬OÓ¤£¿ùªº§Q¦h ¨Ì¥xÁÞ¤j©Ò´£¨Ñªº¸ê®Æ¡A¯ØŦÀù¬O16ºØÀùºØ¤¤³Ì¥ûªº ¥H¤@¯ë¤£©È¬D¾Ôªº¬ã¨s¤Hû¥X¨ªº¸gÀ綥¼hªº¤ß²z¨Ó¤ÀªR Yª¾¦Û¤v¾Ö¦³±j¤jªº²£«~¡A¥h¬D¾ÔÃø«×³Ì°ªªº¥«³õ·|¬OÓÀu¥ýªº¿ï¾Ü ¦ý³Ì«áªº¨M©wÁÙ¬O¥H¤½¥q¤ÎFDAªº¦Ò¶q¬°¥D¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2014/10/31 ¤W¤È 11:56:23²Ä 60 ½g¦^À³
|
¦U¦ì¤j¡G ¤µ¤Ñ¬O10¤ë³Ì«á¤@¤Ñ¡A©ú¤Ñ°_´N¬O11¤ë¤F ¥xªÑ¶qÁY¨ì¨S¦³«Ü¯S®íªºÃD§÷ªºªÑ²¼¡A¬O¤£·|¨ü¨ì§ë¸ê¥«³õªº«C·ýªº §Y¨Ï¦b¥Í§ÞªÑ±Ú¸s¤]¤@¼Ë ¨ì2014¦~¦~©³¯E¹©¥i¯à¥u·|¦³¨âӨ̶i«×»Ýn¤½§iªº°T®§ ¤@Ó¬O¤WÂd¼fij³q¹L¡A¤@Ó¬O833ªºIND³q¹L¥B½T©wn§ðþ¤@ºØÀù ³o¬O¤£¬O§Q¦h¡A¤p§Ì¤]¤£ª¾¡A¦ý³oÄÝ©ó¤@©wn¨«ªº¶i«×¡A®É¶¡¨ì¤F´N·|µo¥Í¡A¤£ºâ¤°»ò¯S§Oªº¨Æ ³Ì¤jªº¦n®ø®§¬O¡A¶i¤J11¤ë¡AÁÙ¬O¨S¦³´Á¤¤¤ÀªRªº®ø®§ ¨C¹L¤@¤Ñ¡A¹L¤@Ó¬P´Á¡A¹L¤@Ó¤ë¡A³£¦bµý©ú¯E¹©ªº»ùÈ»P¤éѼW¡C |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2014/10/31 ¤W¤È 10:50:03²Ä 59 ½g¦^À³
|
²Ä6¶µ§ó¥¿ 6.°²³]822 PFS= 2¦~24Ó¤ë¡AA~C¦ôp¬O¡GA>33 B=33 C<10, ¦ý>5, D¦Ü¤Ö>6 ¥úA~D´N¤w¸g°ª¹L77 °²³]822 PFS=2.5¦~30Ó¤ë¡AA~C¦ôp¬O¡GA=33 B<33,¦ý>17 C<10, D<15, ·¥¥i¯à¤]°ª¹L77 |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2014/10/31 ¤W¤È 10:42:58²Ä 58 ½g¦^À³
|
·PÁ¦U¦ì¤j¤j´£¨ÑÄ_¶Qªº§ë¸ê¸ê°T¡Bª¾ÃÑ»P«Øij¡G ¤p§Ì¤]³ßÅwJ¶Ãºâ¡A¤£§´µ½¤§³B¡AÁÙ±æ«ü¥¿. 1.¨Ì¤½¥q¤½§Gªº¦¬®×¤H¼Æ¡A2012¦~©³¬O99¤H¡A2013¦~6¤ë¬O±µªñ200¤H¡A2013¦~9¤ëªì¬O228¤H¡A2014¦~4¤ë©³¬O314¤H¡A2014¦~8¤ë¦¬®×§¹¦¨342¤H 2.¨Ì¦~³ø©Ò¼g¥Ø«eÂಾ©Ê¨ÅÀùªºPFS¤¤¦ì¼Æ¦b6~9Ó¤ë¡A¥Î³Ì¤j9Ó¤ë¨Ó¦ôp¹ï·Ó²Õ50%, 18Ó¤ë80%, 27Ó¤ë95%´_µo¾÷²v 3.¨ì©ú¦~Q2µ²§ô(6¤ë©³)ªº®ÉÔ¦pªG¤~¸Ñª¼ 4.¹êÅç²Õ»P¹ï·Ó²Õ¨º®ÉÔ¤w¸g´_µoªº¤H¼Æ¦ôp¡G ¦¬®×®É¶¡ 2012/12 2013/6 2013/9 2014/4 2014/8 Total ¶ZÂ÷2015/Q2®É¶¡ 30(¤ë) 24(¤ë) 21(¤ë) 14(¤ë) 10(¤ë) ¹êÅç²Õ¤H¼Æ(¦ô) 66 66 20 57 19 228 ¹êÅç²Õ´_µo(¦ô) A B C D E T ¹ï·Ó²Õ¤H¼Æ(¦ô) 33 33 10 29 9 114 ¹ï·Ó²Õ´_µo(¦ô) 32 30 8 19 5 94 5.¥Ñ©ó¥¼¶W¹L342¤Hªº1/2=171¤H´_µo¡A¦]¦¹T+94<171, T<77 6.°²³]822 PFS= 2¦~24Ó¤ë¡AA~C¦ôp¬O¡GA>33 B=33 C<10, ¦ý>5, ¥úA~C´N¤w¸g°ª¹L71 °²³]822 PFS=2.5¦~30Ó¤ë¡AA~C¦ôp¬O¡GA=33 B<33,¦ý>17 C<10, D<15, ·¥¥i¯à¤]°ª¹L71 7.©Ò¥H¤p§Ì¦ô822 PFS·|>30Ó¤ë¡A·¥¦³¥i¯à¦b36Ó¤ëªþªñ ¦]¬°¤@´ÁMSKCC 4¦~PFS 11/27=41% ¥H¤W¯Âºé¦ôºâ¡AÁÙ¬Onª`·N§ë¸ê·ÀI~~ ±æ¤£§[«ü¥¿ |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/10/31 ¤W¤È 08:01:05²Ä 57 ½g¦^À³
|
¥xÁÞ¤j ÁÂÁ±zÁ`¬OÀ°¦£¤j®a¾ã²z§¹¾ãªº¸ê®Æ °£«D¬O¥Î¥\ªº¯E¤Í¡A§_«h¤HÁ`¬O°·§Ñªº ¦³±z³o»ò¦³¤ßªº¥I¥X¡AÅý¯E¤ÍÌ¥i¥H¦wµM´ç¹L¦h¦¸ªºÅå²^Àb®ö ¯uªºÁÂÁ±z «e¤Ñ¦³¨âµ§³õ¥~¥æ©ö¡A¦³¿³½ìªº¯E¤ÍÌ¥i¥H¦Û¤v¬d¤@¤U ¡]»ù¦ì¤ñ§¡»ù°ª¡^ ¦A¦¸ÁÂÁÂ¥xÁÞ¤j¤Î¼ö¤ßªº¯E¤ÍÌ §ÚÌÄ~Äò¸òµÛ¯E¹©¤½¥q¤@°_¦¨ªø¡B¤@°_¥[ªo £~£¼£~£¼¤j¡A·PÁ±zªº®ø®§¡A§Ú¤]ı±o¤½¥q²{¦b¤@©w«D±`ªº¦£¸L §ÚÌ´NÀR«Ý¤½¥qªº¦n®ø®§¡I¥[ªo¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/10/30 ¤U¤È 11:24:42²Ä 56 ½g¦^À³
|
¦U¦ì¤j¤j: OBI822¯àªvÀøªº16ºØÀù¯g ¤¤, 2014¦~¹w¦ô¬ü°ê¨C¦~¦³¦h¤Ö·s¼W®×¨Ò»P¦º¤`®×¨Ò (Both Sexes) Estimated New Cases , Estimated Deaths (Both Sexes) ¹w¦ô·s¼W®×¨Ò , ¹w¦ô¦º¤`®×¨Ò All Sites 1665540 , 585720 ¨ÅÀù 235030 , 40430 ªÍ»P¤ä®ðºÞÀù 224210 , 159260 ¨xÀù 33190 , 23000 ¤j¸zª½¸z 136830 , 50310 ¤fµÄÀù42440 , 8390 G22220 , 10900 ¯ØŦ 46420 , 39590 ÄáÅ@¸¢ 233000 , 29480 §Z±_21980 , 14270 ¸£Àù 23380 , 14320 ¹¹DÀù 18170 , 15450 µÇŦÀù63920 , 13860 ¤l®cÅéÀù 52630 , 8590 ¤l®c¤º½¤ 12360 , 4020 ¤T³±©Ê¨ÅÀù ¤w¨Ö¤J¨ÅÀùpºâ ÁxÅnÀù 10650 , 3630 ¸ê°T¨Ó·½: Cancer Facts & Figures 2014 - American Cancer Society http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf ª½Àç°Ï°ì: ¬ü°ê¤H¤f:317408015 ¤¤°ê¤H¤f:1361218941 ·s¥[©Y 5076770 »´ä 7173900 «Dª½Àç°Ï°ì ¼Ú¬w±ÂÅv°Ï4¤j°ê¤H¤f : ¼w°ê81751602 ªk°ê65821885 ¦è¯Z¤ú46125154 ·N¤j§Q60626442 ¤é¥»127270000 ¤H ±q¥H¤W¤H¤f²Îp»P¬ü°êÀù¯g²Îp,Ó¤H»{¬°·íOBI822¦¨¥\¤W¥«,§ë¸ê¥xÆW¯E¹©ªº§ë¸ê¤H°£¤F§ë¸ê³ø¹S¥~,³Ì¤jªº¦¬¯q¬O¿n¼w¦æµ½ ¯Î±Ò´fªí¥Ü¡A°£¤F¥i¥H¦b¨ÅÀù²ÓM§ä¨ì³o3Ó¯S©wÁÞ¤À¤l¥~¡A¥t¥~¥]¬AªÍ¡B¨x¡B¤j¸z¡B¤fµÄ¡BG¡B¯ØŦ¡BÄáÅ@¸¢¡B§Z±_¡B¸£¡B¹¹D¡BµÇŦ¡B¤l®cÀV¡B¤l®c¤º½¤¡B¤T³±©Ê¨ÅÀù©MÁxÅnÀùµ¥15ºØÀù²ÓM¤W¡A¤]³£¦³³o3ºØ¯S©wÁÞ¤À¤l¡C¦]¦¹¡A¹wp¥¼¨Ó¥i¥H»s³y¥X¼s®Ä©Ê¬Ì]¡AªvÀø³o¨ÇÀù¯g¡C¥¼¨ÓY¬Ì]¬ãµo¦¨¥\¡A¤£¥u¯à¹ï¨ÅÀù²£¥Í¦³®Ä§ÜÅé¡A´N³s¤Wzªº15ºØÀù¯g¤]·|¦]¦¹µ´¸ñ¡C¥L¼ÖÆ[ªº§Æ±æ¡A¥¼¨ÓÀù¯g¥i¥H¹³¤Ñªá¤@¼Ëµ´¸ñ©ó¥@¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/10/30 ¤W¤È 09:04:56²Ä 55 ½g¦^À³
|
µ½¤H¤j: 1 ¥h¦~§Z±_Àù¤G´ÁÁ{§É¸ÕÅç¦X§@®×¦U¤j´CÅé³£¦³³ø¾É,·j´M¦r¥´(°¨°º ¯E¹© ¤¤®É),³o¤@½g¼gªº³Ì¸Ô²Ó,¦pµ½¤H¤j©Ò¨¥ §Z±_Àù¤G´ÁÁ{§É¸ÕÅç¬O±Ä¶}©ñ¦¡, ¨S¦³¹ï·Ó²Õ, 110¦ì¨ü¸Õ¯f±w¥þ³¡¥Ö¤Uª`®gOBI-822/821,¨ì¤@©w¶¥¬q·|¤ÀªR¾¯¶q»PÀø®Ä, 2¤@¯ë¨Ó»¡°ê¥~¦³¨ÇÃĪ«¬ãµo·|¤½§Gphase2 Á{§Éµ²ªG,¨Ì·Ó¥h¦~11¤ë´CÅé³ø¾É,OBI-822«Ü§Ö´N¯à¬Ý¨ì¤G´ÁÁ{§É¼Æ¾Ú®ÄªG¡A¤£»Ýµ¥¨ì¦¬®×§¹¦¨¡A¥un¹F¨ã°Ñ¦Ò»ùȪº¯f¤H¼Æ¡A´N·|±µ¤â¦VTFDA¥Ó½Ð¶i¦æ¤T´Á·sÃÄÁ{§É¸ÕÅç,®É¶¡ÂI¬O±µªñ¤F |
|
|
·|û¡G¤p±j10137673 µoªí®É¶¡:2014/10/30 ¤W¤È 08:13:30²Ä 54 ½g¦^À³
|
¥x¥_°¨°º¥i¯à¦b11¤ë·|¥l¶}°OªÌ·|,«Å§G¦³Ãö822§Z±_Àùªº¸ÕÅçµ²ªG,¦]¬°¸ÕÅç§Y±Nº¡¤@¦~¤F¡C ½Ð°Ý¦³½T©w¶Ü¡C |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2014/10/30 ¤W¤È 12:17:06²Ä 53 ½g¦^À³
|
°¨°º»P¯E¹©¦X§@ªº§Z±_Àù¤G´ÁÁ{§É¸ÕÅç¬O±Ä¶}©ñ¦¡, ¨S¦³¹ï·Ó²Õ, 110¦ì¨ü¸Õ¯f±w¥þ³¡¥Ö¤Uª`®gOBI-822/821, ¸g¹L¤T©Î¥|Ӥ몺ªvÀø«á, Âå¥Í©M¯f¤H´Nª¾¹D¯f±¡ªº¶i®i : 1. §ïµ½¤F, ¸~½FÁY¤p¤F, 2. ¨S¦³¶i®i, ¸~½FÁÙ¬O¨º»ò¤j, 3. ´c¤Æ¤F, ¸~½FÅܤj, Àù²ÓMÂX´². ¸û¦°Ñ¥[ªº¯f±w, ¤w¸g§¹¦¨ªvÀø, ¤w¸gª¾¹DOBI-822/821¹ï³o¨Ç¯f±wªºÀø®Ä¬O¦n©Î¤£¦n, ¦nªº¦³´X¤H, ¤£¦nªº¦³´X¤H, ¤º¦æ¤HÀ³¸Ó³£ª¾¹D¤F. ¦pªG¯E¹©ªºªÑ»ù¦³¤H¦b·ÓÅUªº¸Ü, ³o¨Ç¤H·|¤£·|·Q¿ìªk¥hÁA¸Ñ¨ü¸Õ¯f¤Hªº±¡ªp, ¥ç§YÁA¸ÑOBI-822/821ªºÀø®Ä. ¦pªG¯f¤Hªº¯f±¡¨S¦³§ïµ½©Î´c¤Æªº¤ñ¨Ò¤ñ¸û°ª, ¯E¹©ªºªÑ»ù·|«ç»ò¨«? ÁÙ·|°ª°ªªº¦b400¦h¤¸¹C¨«¶Ü? ³o´N¬O¤§«e§Ú»¡ªº, ¥ýª¾¥ýıªºÁo©ú¿ú·|¤@¨B¤@¨Bªºµe½u¸ô¹Ïµ¹§ë¸ê¤j²³¬Ý. |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2014/10/29 ¤U¤È 04:15:46²Ä 52 ½g¦^À³
|
¹d¦ëºô¥h¦~6¤ë³ø¾É "¿³Âd·sÃļt¥xÆW¯E¹©(4174-TW)¸³¨Æªø±i©À·O¼ÖÆ[«ü¥X¡A¤½¥q·sÃĶi«×«ùÄò¶W«e¡I¨ä¤¤ÀòTFDA®ÖãªvÀø¥½´ÁÂಾ©Ê¨ÅÀùªº¬Ì]OBI822/821¡AÁ{§É¶i«×¶W«e¡A³Ì§Ö©ú¦~º©u§¹¦¨¦¬®×¡A¨Ã¶i¦æ¼Ú¬ü3´ÁÁ{§É¸ÕÅç¡C¦Ó°£¨ÅÀù¥~¡Aµu´Á¤º¤]±N·s¼W§Z±_Àù¾AÀ³¯g¡A¦Û2´Á¶}©l±Ò°Ê¡C¥t¥~¦b·s¤@¥NÀù¯g§K¬ÌªvÀøªºOBI-833³¡¤À¡A²Ä¤@Ó¾AÀ³¯gÂê©w¥½´Á¯Ø¸¢Àù¡A¹wp©ú¦~¶i¤J¤HÅéÁ{§É¡C ¯E¹©°£ì¦³ªvÀø¥½´ÁÂಾ©Ê¨ÅÀùªº¬Ì]OBI822/821¡A¥h¦~ÀòTFDA®Öã¶i¤J3´Á¤HÅéÁ{§É¸ÕÅç¥~¡A½T©w²Ä¤GÓ¾AÀ³¯g¬°§Z±_Àù¡C¥t¥~¡A¦Û¤¤¬ã°|±ÂÅvªº·s¤@¥NÀù¯g§K¬ÌªvÀøOBI833¡A¤]½T©w²Ä¤@Ó¾AÀ³¯g¬°¥½´Á¯Ø¸¢Àù¡A¹wp©ú¦~¶i¤J¤HÅéÁ{§É¡A²Ä¤GÓÔ¿ï¾AÀ³¯g«h·|¬OªÍÀù¡C¨ä¤¤OBI822/821¡A©ú¦~²Ä¤@©u´N±N§¹¦¨¦¬®×¡A2016¦~ÃÄ«~´N¥i¥H¤W¥«¾P°â¡C" ±i©À·O«ü¥X¡A°£¤F¨ÅÀù¥~¡AOBI822/821µu´Á¤º±N¶i¦æ§Z±_Àùªº¾AÀ³¯g¡A¥B¦]¦w¥þ©Ê¤w³QÃÒ¹ê¡A±N·|±q2´ÁÁ{§É¤Á¤J¡A®É¶¡·|¸`¬Ù³\¦h¡A¥t¥~¥¼¨Ó¦Ò¶q¾P°â³q¸ô¡A¼Ú¬w¤Î¤é¥»ªº¾P°â¥i¯à¹ï¥~±ÂÅv¡C" 1.²{¦b¬Ý°_¨Ó¡A¦¬®×§¹¦¨µy·L±ß¤@¨Ç±qì©wQ1¨ì8¤ë¡A©Ò¥H¶¶§Qªº¸Ü·sÃĤW¥«¬ù²ö¦b2016~2017¤W¥b¦~§a¡C 2.¥t¥~§Z±_Àù¤]¤w¶i¦æ±Nªñ¤@¦~¡A¤£ª¾110¦Wì©w¦¬®×¤H¼Æ¬O§_¦¬º¡¤F? ¥H¤Î¹êÅç¹wp¦ó®É§¹¦¨? 3.OBI-833¯ØŦÀùÁ{§É´ú¸Õ¡A¬O§_·|¦p¥h¦~¹w¦ô¦b2014¦~®i¶}? ³o¤T¶µ¤]¬O¦bÃöª`822¨ÅÀù¤T´Áµ²ªG¥XÄl«e¥i¥HȱoÃöª`ªº¨Æ±¡ |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2014/10/29 ¤U¤È 03:42:34²Ä 51 ½g¦^À³
|
£~£~¤j.. "..§Ú¬O¦oªºªB¤Í,¦oª½±µ¥D°Ê°Ý§Úªº.."¤@¤â¸ê°T¶WÆg. ¥i§i¶D¦o.¥xÆW·sÃĬãµo¯à¤O¶WÆg.(¯Î°|ªøºtÁ¿´£¨ì..¤@´Áªº¸ÕÅçµ²ªG¦n¨ì¬ü°ê¤H"¤£¬Û«H") ¦Ó¥B§ë¸ê¥«³õ¹ï¥~°ê¤H¤Íµ½.¦on¥æªºµ|¤ñ§Ṳ́Ö...(§Ú¨S¦³n°Q½×ÃÒ©Òµ|) ÁÂÁ£~£~¤jªº¸ê°T.. |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2014/10/29 ¤U¤È 03:19:03²Ä 50 ½g¦^À³
|
¥P?§Ú±`±`¨S¬~¾þ,¨¤W¦³«Ü¦h¥P,¤]±`±`¡u¤J¥P¡v¡C ²Ä1.ÂI,§Ú¬O¦oªºªB¤Í,¦oª½±µ¥D°Ê°Ý§Úªº¡C´N¬O³o»ò²³æ,¨S¤°»ò¯«¯µ¡C ¦]¬°¦o»¡¦o¹ï822«D±`¦³«H¤ß!³£Âಾ¨âÓ¾¹©xÀù¥½²Ä¥|´Á¤F (¨ÅÀù¤À´X´Á§r?§Ú°O±o¦o»¡¬O²Ä¤´Á,¦Ó¥B¦o»¡¬OOPT-822), ³oºØª¬ºAÅÜNED¬O¦h»ò¾_¾Ù,¦h»òÅå³ßªº¨Æ§r! ªÑ²¼§ë¸ê·ÀI«Ü¤j,½Ð¤£n³Q§Ú»~¾É,§Ú»¡ªº¸Ü¬O¨S¦³¨DÃÒªº,¤£¨¬±Ä«H¡C ĹÁ«¦Ût,Ä@½äªA¿é¡C |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2014/10/29 ¤U¤È 02:23:09²Ä 49 ½g¦^À³
|
¥»ª©¥i¯à¯u¦³¤£±o¤Fªº¤Hª«.. Cliff¤j --¯«¯Å ¤w¸ò§d³Õ¤h½T»{¹L....... ¤U¤È±µÀò°|ªø¦^ÂÐ:¡uYes, you are right. Thank you.¡v ÁÙ¦³¥P¯Åªº£~£~¤j 1.¼w¦{¨º¦ìNEDªº±wªÌ,¦o¤£¦ý«ùÄòNED,¦Ó¥B¦o¤]·Qn¶R¯E¹©ªÑ²¼¡C¥i¬O,¦o¤£ª¾¹D¬ü°ê¤Hn¦p¦ó¶R,§Ú¤]¤£ª¾¹D¡C«¢«¢! 2.¥x¥_°¨°º¥i¯à¦b11¤ë·|¥l¶}°OªÌ·|,«Å§G¦³Ãö822§Z±_Àùªº¸ÕÅçµ²ªG,¦]¬°¸ÕÅç§Y±Nº¡¤@¦~¤F¡C §Ú¤]«Ü¦n©_..£~£~¤j 1.ªº³¡¤À±qþ±oª¾ªº?? |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2014/10/29 ¤W¤È 06:37:43²Ä 48 ½g¦^À³
|
¯E¹©·sÃĦpªG¬ãµo¦¨¥\,¯E¹©±N·|¦¨¬°»OÆW¦Ê¦~Ãø¨£ªº¤j¶Â°¨,ÁöµMÁôÂäֳ\·ÀI,¬Û«H¹LÃö¾÷²v·|«Ü°ª,¥[ªo§a!¦U¦ì¯E¤Í . |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2014/10/29 ¤W¤È 12:19:33²Ä 47 ½g¦^À³
|
¤j®a´Nťť £~£~¤j©Ò§i»|ªº,¬°¤F¯E¹©¦n@¤ßªºµ¥«Ý§a,²¦³º§Z±_ªº¬ã¨s¸ÑÃĮİ£¤F¨Å©Ð¯f¯g¥H¥~¦hªºÅå©_ÂI!! |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2014/10/28 ¤U¤È 11:59:52²Ä 46 ½g¦^À³
|
£°!¤£n¥X²{¤@°ï¦Û¨p¤H,¬°¤F¦Û¤vªºªÑ²¼°T®§,¥´¹q¸Ü¶Ã°ÝÄÌÂZ¤H®a,¤H®a°µ¬ã¨s¦£ªºn©R,¦pªG¦A±µ¨ì³oºØ¹q¸Ü,¥»¨Ón¶}³£·|Åܨú®ø¤F¡C¥xÁÞ¤j,§Ú¤£¬O¦bÁ¿§A¡C§Ú¬O¦bÁ¿¤@°ï¤£°µ¥\½ÒªºÄêµu½u«È! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/10/28 ¤U¤È 10:56:08²Ä 45 ½g¦^À³
|
£~£~¤j §Aªº¸ê°T¨º¨Óªº¡H ·|¤£·|¬On¶i¤J¤T´Á ¥jô·j´M¦r : ¯E¹© °¨°º ¤¤®É ·|¦³¥h¦~¤Q¤@¤ë§Z±_Àù¸ê°T |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2014/10/28 ¤U¤È 09:54:18²Ä 44 ½g¦^À³
|
1.¼w¦{¨º¦ìNEDªº±wªÌ,¦o¤£¦ý«ùÄòNED,¦Ó¥B¦o¤]·Qn¶R¯E¹©ªÑ²¼¡C¥i¬O,¦o¤£ª¾¹D¬ü°ê¤Hn¦p¦ó¶R,§Ú¤]¤£ª¾¹D¡C«¢«¢! 2.¥x¥_°¨°º¥i¯à¦b11¤ë·|¥l¶}°OªÌ·|,«Å§G¦³Ãö822§Z±_Àùªº¸ÕÅçµ²ªG,¦]¬°¸ÕÅç§Y±Nº¡¤@¦~¤F¡C |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2014/10/28 ¤U¤È 06:17:30²Ä 43 ½g¦^À³
|
±i¸³¤£ª¾¦³¨S¦³¦b¬Ý³o°Q½×°Ï,¦pªG¦³§Ú·Q¥L¤]·|¥s¦n! |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/10/28 ¤U¤È 05:28:58²Ä 42 ½g¦^À³
|
¥xÁÞ¤j ·PÁ¸ɥR ¨S¿ù ¯E¹©³ÌÁo©úªº¦a¤è´N¬O¥iÁp¦X¥ÎÃÄ ±i¸³¤£·\¬O¦³¹ê¾Ô¸gÅ窺¥Í§Þ°ª¤â Æg¡I¶WÆg¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/10/28 ¤U¤È 05:16:55²Ä 41 ½g¦^À³
|
Faith¤j: ¯E¹©ªº¥ÎÃĵL½×¯f±w¥Ø«e¬O§_¦³¨Ï¥Î¤ÆÀøÃĪ«.©Î±µ¨ü¹L©ñÀø ³£¥i¥ÎÃÄ,°ß¤@¥u¦³¹ï¶PÀù¥¦³®Äªº±wªÌ¤£«Øij¥ÎÃÄ §Úªº»{ª¾¦ü¥G¤£¬O¦p¦¹,2013¦~©³Á{®ÉªÑªF·|§Ú¦³°Ý:¯E¹©¬O§_·|Á׶}¶PÀù¥Her2¶§©Ê25% 6 0»õ¬ü¤¸¥«³õÂ੹¶}©Ý ¥t¥~75%¥«³õ,¶ÀÁ`Â_µM©Úµ´¦p¦¹»¡ªk,³oªí¥Ü¯E¹©n¦û»â¨ÅÀù¥þ³¡¥«³õ(¤T¦]©Ê ¶Pº¸»X¶§©Ê»PHer2¶§©Ê),³oÓ¥«³õ¤w¸g«Ü¤j¤F, µM¦Ó¯E¹©³Ì¤j°Ó¾÷¥«³õ¦b¹w¨¾©Ê¥ÎÃÄ,¤ÎÁp¦X¥ÎÃÄ,°ß¦³Áp¦X¥ÎÃĤ~¯à¶}ÅP§ó¤j¥«³õ,Áp¦X¥ÎÃĤ£ªí¥Ü¬ãµoªºÃĤ£¦n¦Ó¬O°Ó·~¦XÁa³s¾îªºµ¦²¤¦Ò¶q,¤]³\§O¤HªºÃÄ¥u¼W¥[6¦Ü12Ó¤ëPFS ,¦]Âå¥Í¤w²ßºD¥ÎªºÃÄn¤@¤U©ñ±ó¤£¤Ó®e©ö, X+822 , X+Y+822, ¦p 888+822 , µµm¾J+822, Cyclophosphamide+822, ¶PÀù¥+822 , ¶PÀù¥+¶P¯e§´+822 , ´N¥i¯à·|¥X²{ |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/10/28 ¤U¤È 03:46:08²Ä 40 ½g¦^À³
|
¥xÁÞ¤j.ÂŤѤj.¦U¦ì¤j¤j ¥Ø«e822ªºÁ{§É¹êÅç«Ç822+Cyclophosphamide ¥¼¨ÓÃÄ«~¤W¥««á ²z½×¤]À³¸Ó¥HÁ{§Éªº¹êÅçµ¹ÃÄ ÁöµM¤ÆÀøÃĪ«·|³y¦¨°Æ§@¥Î ¦ý§Ú»{¬°±q²Ä¤@´Á¨ì²Ä¤G´Á ¾ú¸g¤F10¦~ ¤½¥q¦³³Ì§¹¾ãªº¦Ò¶q ¸³¨Æªø±i©À·O¯uªº«ÜÁo©ú ¯E¹©ªº¥ÎÃĵL½×¯f±w¥Ø«e¬O§_¦³¨Ï¥Î¤ÆÀøÃĪ«.©Î±µ¨ü¹L©ñÀø ³£¥i¥ÎÃÄ °ß¤@¥u¦³¹ï¶PÀù¥¦³®Äªº±wªÌ¤£«Øij¥ÎÃÄ Áo©ú¦bþ?¯E¤Ḭ́ʸ£·Q·QÅo (°e³ø¤j,§A³o¤@¼ç,¤Ó¤[¤F§a,«¢«¢«¢) ¥H¤WY¦³»~,©|½Ð´£¥X§ó¥¿,·PÁ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/10/28 ¤U¤È 03:30:26²Ä 39 ½g¦^À³
|
ÂŤѤj: ÁÂÁ§Aªº«ü¥¿,¶PÀù¥ À³¦³¥[¤@¨Ç¤ÆÀøÃĤ~·|¦³150¦Ü440²@§J ,¯u¥¿¶PÀù¥¦p¤£¥[¨ä¥LÃĪ«¤£¤§¾¯¶q¦h¤Ö? Åó±ø±ø¤j: §A¼gªº¤ñ§Ú¦n,§óÅý¤H¦³·P |
|
|
·|û¡GÂŤÑ10138178 µoªí®É¶¡:2014/10/28 ¤U¤È 03:17:42²Ä 38 ½g¦^À³
|
¥xÁÞ¤j §Ú²q´ú©Î³\OBI-822©Ò¿×ªº¥´°w ¥i¯à©M§Ú̦L¶H¤¤¦³°wÀY©M°wµ©ªº¦L¶H¤£¤@¼Ë ¦pªG¬O¶Ç²Îªºª`®g ³o»ò¤Öªº¾¯¶q ¥i¯àª`®g§¹«áÁÙ¦³´Ý¯d¦b°wµ©¤º ´N¹F¤£¨ìª`®g¤@°w30·L§Jªº¾¯¶q¤F. |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2014/10/28 ¤U¤È 03:01:55²Ä 37 ½g¦^À³
|
¥xÁÞ¤j¡A¼g±o¯u¦n¡A¤p§Ì¤]¨ÓÄmÁà¤@¤U ©ú¤ë¦è¨I¡A¿ú²^ºÉ¡A¤d¸U¨¯»ÄªÑ¥Á¡C »S×UªFÃä¡A¤H¹D¬O¡Aªk©ç©P¦¤½´J¡C Å¥«H¤º½u¡A°l°ª±þ§C¡A¿é¤F¤@¿Ç¤l¡F ª÷»È¦pµe¡A§l¤Þ²³¦h¦n¤â¡C »»·Q¤½½@·í¦~¡A¤p³ìªì¶ù¤F¡A¶¯«º^µo¡C ºô¸ô¤U³æ¡A½Í¯º¶¡¡A»«¤h»´ÃP¤J³U¡C ª÷¿Ä®ü¼S¡A½ß¥úÀ³¯º§Ú¡A³»¤WµLµo¡C «e¥Í¦p¹Ú¡A«á¥ÍÁÙô¯E¹©¡C ¤£¬O§Úªº¼g·Ó¡A¥u¬O¯Âºé¥´¥´ªo¡A·i§g¤@¯º~~ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/10/28 ¤U¤È 01:19:15²Ä 36 ½g¦^À³
|
Ĭ¸ý ©À¥£¼b ¨ª¾ÀÃh¥j ¤j¦¿ªF¥h¡A®ö²^ºÉ¡A¤d¥j·¬y¤Hª«¡C ¬GÂS¦èÃä¡A¤H¹D¬O¡A¤T°ê©P¦¨ª¾À¡C ¶Ã¥Û±Y¶³¡AÅåÀܵõ©¤¡A ±²°_¤d°ï³·¡F ¦¿¤s¦pµe¡A¤@®É¦h¤Ö»¨³Ç¡C »»·Q¤½½@·í¦~¡A¤p³ìªì¶ù¤F¡A¶¯«º^µo¡A ¦Ð®°ºú¤y¡A ½Í¯º¶¡¡A±j¸¸¦Ç¸·Ï·À¡C ¬G°ê¯«¹C¡A ¦h±¡À³¯º§Ú¡A¦¥ÍµØµo¡C ¤H¥Í¦p¹Ú¡A ¤@´LÁÙät¦¿¤ë¡C §ï¼g Ĭ¸ý ©À¥£¼b ¨ª¾ÀÃh¥j ®ü¼S¦è©b¡A®ö¨RË¡A¼Ú¬ü¥Í§Þ¤½¥q «n´ä¨ºÃä¡AÂå¹D¬O¡A°ò¦]Å餤¤ß ¯E¤jÁn¶Õ¡A¥þ²y´Á¬ß¡A±²¨«¤d»õ¤¸ ¬ü´º¦p¸Ö¡A ¤@®É¦h¤Ö¾ÇªÌ »»·Q¥ýª¾·í¦~¡A±´¯ÁÁÞ¤À¤l¡A®ð¦t°a©ù ¥Õ³TªA¹¢¡A±Mª`¶¡,´cÅ]¥þ¼ÆÄè·À «¦^¥xÆW¡AªB¤ÍÀ³»¡§Ú¡AÃh©êÄ@´º ·³¤ë¦p±ô ¡A¤@¤ß¦^³ø¬G¶m |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/10/28 ¤W¤È 11:11:49²Ä 35 ½g¦^À³
|
OBI822 ¤£¥i«äijªº§C¨Ï¥Î¾¯¶q ,Ãø©Ç°Æ§@¥Î ¬r©Ê§C¨ì¤£¦æ,«Ü¦h¤T´ÁÁ{§É³q¤£¹LFDA¼f¬d¬O¦]¬°°Æ§@¥Î ¬r©Ê»P¦w¥þ©Ê Ó¤H¬ù²¤pºâ: 1²@§J¬O1000·L§J OBI822¨C°w¥Î¶q30·L§J ¤@Àøµ{9°w270·L§J ¦pªG1²@§J¥i»s³y¥X30°w (¦©°£»Ý®ø¯Ó±¼ªº) ¦©°£OBI822¤@Àøµ{9°w«á ¶PÀù¥¥´¤@°wªº¾¯¶q ¥iÅýOBI822ªº¯f±w¨Ï¥Î¦~¼Æ (¨C¦~4°w) Trastuzumab(¶PÀù¥á´¹ª`®g¾¯)440²@§J X30 =13200°w(¶PÀù¥¥´¤@°wªº¾¯¶q ¥iÅýOBI822ªº¯f±w¸g¹L¤@Àøµ{«á¥i¦A¨Ï¥Î3297.75¦~) Trastuzumab(¶PÀù¥á´¹ª`®g¾¯ 150²@§J X30 = 4500°w(¶PÀù¥¥´¤@°wªº¾¯¶q ¥iÅýOBI822ªº¯f±w¸g¹L¤@Àøµ{«á¥i¦A¨Ï¥Î1122.75¦~) ¥H¤W´£¨Ñ¯E¤Í°Ñ¦Ò ¦p¦³¿ù»~½ÐÀ°¦£§ó¥¿ |
|
|
·|û¡G¤p±j10137673 µoªí®É¶¡:2014/10/28 ¤W¤È 10:13:07²Ä 34 ½g¦^À³
|
¤S¹L¤F¤@Ó¤ë.Â÷¦¨¥\¤S±µ¶i¤@¨B.µu´Á¾_Àún§Ô@.¤£n²z·|¨ä¥L.©¹§Ú̥ؼЫe¶i. |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2014/10/26 ¤U¤È 11:06:21²Ä 33 ½g¦^À³
|
¥xÁÞ¤j, «D±`·PÁ±z´£¨Ñªº¸ê°T! ¯E¹©Ä@´º ¯E¹©µo®iµ¦²¤¡A§Y¥ß¨¬¥xÆW¡B©ñ²´¥þ²y¡F¥Ú§Ó¥H¥xÆW«~µPªº³Ð·s·sÃÄ¡A¦æ¾P¥þ¥@¬É¡G µuµ{¤Î¤¤µ{¥Ø¼Ð¡A§Y¦b 2015 ∼ 2025 ¦~´Á¶¡¡A Ãk¦V¥xÆW¥Í§Þ»sÃĬɰª®p¡A¦¨¬°¥xÆW³»¦y NO.1 ¥Í§Þ»sÃĤ½¥q¡F ªøµ{¥Ø¼Ð«h¦b 2035 ¦~¡A¦¨¬°¥þ²yÀù¯g§K¬ÌÀøªkªº»â¯èªÌ¡C ¯E¹©Àç¹Bµ¦²¤ ¥xÆW¯E¹©ªº¥|¤j¥ø·~Àç¹Bµ¦²¤¡G 1. ¬ãµo¸}¨B¥Ã¤£°±·²¡G¥H¿W®aOPopSTM ™ÁÞ¶}µo¥¥x¤Î¦yºÝ§K¬ÌªvÀø·s¬ì§Þ¡A©Ý®i¬ÛÃö²£«~½u¡C 2. ±j¤Æ¨Ã©P¥þ²£«~½u¡G²£«~¬ãµo¦¨¥\§Y¶i¤@¨B°Ó«~¤Æ¡A¨Ã¤Þ¶i·s²£«~¤Î§Þ³N¡A±j¤Æ²£«~½u¨Ã¨Ï¤§§¹¾ã¡C 3. ¥´³y³»¦y»â¾É«~µP¡G«Ø¥ß¥xÆW«~µPªº«~½è«Oµý¡A¨Ã¥´¶}°ê»Úª¾¦W«×¡A¦æ¾P¥þ²y¡C 4. ³Ð³y²£«~³Ì°ª»ùÈ¡G³z¹L¸ó°Ï°ì¥þ²yµ²·ùµ¥¤è¦¡¡A ±N²£«~»ùÈ·¥¤j¤Æ¡C ¯E¹©¦b±i¸³©M¤¨¦ÑÁ󵥤Hªº»â¾É¤U, ¤£¶È¦³¥ø·~©MªÀ·|ªº³d¥ô¤ß, §ó¦³±ÏÀù¯g¯f¤H, ¤×¨ä¬O±Ï§U³h®zÀù¯g¯f¤Hªº·Oµ½¤ß. ¦³¤½¸q¤ß, ¦³·Oµ½¤ßªº¥ø·~©M¥ø·~®a±N·|¦Û§U ¤H§U ¤Ñ§U! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/10/26 ¤W¤È 09:42:00²Ä 32 ½g¦^À³
|
¸³¨Æªøªº¸Ü--°l¨D¥Í©R»P°·±dªºªÀ·|¤½¸q,¯E¹©¥ø·~ªÀ·|³d¥ô³ø§i®Ñ «Ü¦´N¦³¤H¹w´ú¡A¥Ø«e¸ê°T¸gÀٮɥN¤wªñ§ÀÁn¡A ¹L¤F21 ¥@¬ö«e´Á¡A¤H̱N·Ç³Æªï±µ¥t¤@Ó¥þ·s ®É¥N¡X¢w¥Íª«¸gÀٮɥNªº¨ÓÁ{¡C±q·í«e¥Í§Þ¦Ê®a»ô»ï¡BªÑ¥«¦æ±¡¹ð³Ð·s°ª¬Ý¨Ó¡A¥Í§Þ·~ªº¿P¤l¦ü¤w ¨ì¨Ó¡C ¦ý¬O¡A¬Û«H±q¨Æ¥Í§Þ·~ªÌªºªì¤ß¡A³£¤£¶È¤î©ó³Ð³y¤@ӥͧ޲£·~ªº¸gÀÙ²±ªp¡F¦bÁa¨³oÓ»â°ì«e¡A ©TµM¤w´x´¤¤F¬ÛÃöªº±M·~ª¾ÃÑ»P§Þ³N¡A¤]¬Ý¨ì¤F¥xÆWªº±ø¥ó©M»W¿nªº¯à¶q¡A§Æ±æ±a»â¤j®a¦@¦P°l¨D ³oÓ²£·~ªºÄ@´º¡F¦ý¡A§ó¤jªº°Ê¤O¤´¦b¸Ñ¨M°ÝÃD©M»Ý¨D¡A¤×¨ä¬O¸Ñ¨M¯f¤HªºµhW©M¹ïªvÀøªº»Ý¨D¡C ´«¨¥¤§¡A²£·~¦A°_¸¡B¤½¥q¦A¤j¡BÀò§Q¦A¥iÆ[¡A¤£n§Ñ¤F¥Í§Þ»sÃIJ£·~ì´N¬O¥Í©R¨Æ·~ªº¤@Àô¡A ¦o©M§Oªº²£·~³Ì¤j¤£¦P¡A§Y¦b»P¤H¸s¡B¥Í©RÃì±µ¦b¤@°_¡A¥²¶·³B³B¥H¦¹¬°©À¡A´L«¥Í©R¡A¬°¯f±w³yºÖ¡A ³o¬O¥Í§Þ»sÃĤ½¥q³Ì«nªº¥ø·~ªÀ·|³d¥ô¡C Ó¤H¦b¦Û¦æ³Ð·~«e¡A´¿¥ô¾°ê»Ú¤jÃļt¡A·í®É¤ÆÀøÃÄ«~¦]À³Àù¯g¥«³õÃe¤j»Ý¨D¡A¾P°â¶q¿E¼W¡F ¦Ó¤ÆÀøÃÄ«~ÁöµMÀ°§U¤FÀù¯g¯f¤Hµ´³B³{¥Í¡A¦ý¥Ø¸@¤ÆÀø¹Lµ{¤¤¯f±w¨üºÉªº§é¿i¡A«o¤£§K·P´n¡F¯f±w ±Ï¦^¨Óªº©R¡A¥u³Ñ¤U¤@¥b¡F¥HÂå¾Ç©MÃÄ«~¬ì§Þªºµo¹F¡AÀ³¦³§ó¦hªºÂå¾Ç®a¡B¬ì¾Ç®a§ë¤J¡A¬ãµoªvÀø ®ÄªG§óÀu¶V¡B§ó¤H©Ê¤ÆªºÃÄ«~¡F³o¤]¬O¦ó¥H¯E¹©¥H·sÃĬãµo¦Û§Ú©w¦ì¡A¨M¤ß¬D¾Ô¨Ãº¡¨¬¤´¥F¦³®ÄÀø ªkªºÂåÀø»Ý¨D¬°¨Ï©R¡C§Ú̪º¥Ø¼Ð¡A¤£¤î¦b°l¨D³Ð·s¡B¦³®ÄªºÂåÀø¡A§ó¦bÀ°§U¯f±w¦b¹ï§Ü¯e¯f¦P®É¡A ¤´¯à«O¦³¥Í©R´LÄY¡A¨É¦³¥Í¬¡«~½è¡C ¤£¥i§_»{ªº¬O¡A·sÃÄ°Ý¥«¥²Åý³\¦h¯f±w¤ÞÀV¥H«Ý¡A¦ý¬O¡A¶}µo·sÃĤ£©ö¡A¦¨¥»§ó¥O¤H©Q¦Þ¡A¦] ¦Ó·sÃÄ°â»ù¦h¥b¥iÆ[¡FY¥¼¥ÑªÀ·|«OÀIµ¹¥I¡A¥²µMÅý³\¦h°]¤OµLµÛªº¯f±w±æ¤§¿³¼Û¡A¤]¤j¤j«]¤F ·sÃĨü´fªº±Ú¸s¡F³o¬O¦Û¥Ñ¸gÀÙ¥«³õ¾÷¨î¨ÏµM¡A«o¤£¬O·sÃĬãµoªºªì°J¡C ÀHµÛ¯E¹©¬ãµoªº¨ÅÀù·sÃÄOBI-822 Á{§É¸ÕÅç¶i®i¡A§Ṳ́]·Q¨ì¥¼¨Ó¶¶§Q¤W¥«ªº¸Ü¡A³oÓ¥²µM± Á{ªº«¤j°ÝÃD¡F¤]¦]¦¹¡A§Ú̪ì¨Bpµe¡G¥¼¨Ó¯à¦¨¥ß¤@Ó°òª÷·|¡A¥H°âÃĬվlªº¤@©w¤ñ¨ÒѺª`°òª÷¡A ±Mªù¨ó§UµL¤Ot¾áªº¯f±w±µ¨ü·sÀøªk¡AÅý¨CÓ¤H°l¨D°·±dªºÅv§Q¤£¦]¸gÀÙª¬ªp¦Ó¦³®t§O¡C ³o¬O§Ú»{¬°¥Í§Þ¥ø·~³Ì«nªºªÀ·|³d¥ô¡A¦b§JºÉ¤½¥qªv²z¡Bªk³W¿í±q¡BÀô¹Ò«OÅ@µ¥°ò¥»³d¥ô¤§ ¥~¡AÀ³¸Ó¦^¨ì§Ú̱q¨Æ³o¤@¦æªºªì¤ß¡G¦p¦ó±Ï§ó¦h¥Í©R¡H¦p¦ó´î»´§ó¦h¤HªºµhW¡H¦p¦ó°µ¨ì°·±d¥ Åv¡AÅý¥Í©Rªº»ùȨ㦳¦Pµ¥´LÄY¡H±q³oÂI¥Xµo¡A«ä¦Ò¨Ã¸¨¹ê§ó¼e¡B§ó¼sªºªÀ·|¤½¸q»P¤½¯q¡A³o¬OÀu ½è¥ø·~ªºªÀ·|³d¥ô¡A¤]¬O¯E¹©¹ïªÀ·|ªº©Ó¿Õ¡C http://www.obipharma.com/chi/images/inside/csrreport.pdf |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/10/25 ¤U¤È 04:48:25²Ä 31 ½g¦^À³
|
¤U¤È±µÀò°|ªø¦^ÂÐ:¡uYes, you are right. Thank you.¡v |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/10/25 ¤W¤È 09:49:29²Ä 30 ½g¦^À³
|
11¤ë1¤é¬P´Á¤» ¤¤¬ã°|¶}©ñ°ÑÆ[¸ê°T ¯S§O¬¡°Ê Special Activities ¬ì´¶ºtÁ¿ Popular Science Lectures ¾Ç³N®y½Í·| Academic Symposium ¬ã¨s¦¨ªG®i Display of Research Achievements ¥Xª©«~®i Exhibitions of Publications ¶}©ñ°ÑÆ[ Open House Visit ¼v¤ù©ñ¬M Film Presentations ¨ä¥L¬¡°Ê Other Activities ¬¡°Ê¼úÀy¤è¦¡ How to Obtain a Prize °|°Ï¹Ï Campus Map of Academia Sinica http://www.sinica.edu.tw/openhouse/2014/ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/10/25 ¤W¤È 09:38:07²Ä 29 ½g¦^À³
|
Cliff¤j µ½¤H¤j: ¤¤¥¡¬ã¨s°|ºô¯¸ ½T©wDT ¬O¥Õ³ïÃþ¬r¯À,¯E¤Í¦³°Ñ¥[ªÑªF·|³£ª¾¹DDT¬O¥Õ³ïÃþ¬r¯À,½Ã¥ÍºÖ§Q³¡ºô¯¸ ¬Ì]¤¤^¤å¦WºÙ¤Î²ºÙ¹ï·Ó¤@Äýªí ¤¤ªºDT ¬Ý°_¨Ó»P 833 ªº DT À³¸Ó¤£¤@¼Ë ,¬°¤FÀ±¸É¦Û¤vªº±À½×¥¢»~´£¨Ñ¥H¤U¸ê°T¸ÉÀv 11¤ë1¤é¤W¤È9®É¨ì16®É±N¶}©ñ°|°Ï°ÑÆ[¡A¤µ¦~¾A³{¤¤¬ã°|¾E«Ø«n´ä°|°Ïº¡60¦~¡A¬¡°Ê¥D¶b¬°¡u«n´ä¤@¥Ò¤l ¦^¾Ð¤@§X¤l¡v¡A®i²{¤¤¬ã°|¹L¥h¾Ç³N¤ã®Úªº¾úµ{¥i°ÑÆ[°ò¦]Å餤¤ß, °|°Ï, »ö¾¹³]³Æ.¤]¦³ºtÁ¿,¥i°Ý«Ü¦h°ÝÃD http://udn.com/NEWS/BREAKINGNEWS/BREAKINGNEWS1/%E4%B8%AD%E7%A0%94%E9%99%A211%E6%9C%881%E6%97%A5%E9%96%8B%E6%94%BE%E5%8F%83%E8%A7%80-9010803. |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2014/10/25 ¤W¤È 02:11:31²Ä 28 ½g¦^À³
|
Cliff¤j, «D±`·PÁ±z! §Ṳ́S¤W¤FÄ_¶Qªº£¸°ó½Ò. ¥xÁÞ¤j, ¤U±³o½g¯Î°|ªøªº½×¤å, ¤]»¡©úCliff¤j¬O¹ïªº: diphtheroid toxoid cross-reactive material (CRM) 197 (DT), DT¬Odiphtheroid toxoid ¥Õ³ïÃþ¬r¯ÀªºÂ²¼g. ¨SÃö«Y, ¦³°ÝÃD´N´£¥X¨Ó°Q½×, ¤~¯à¤¬¬Û¾Ç²ß¯¡Ày¦¨ªø¶i¨B, ³o¬O§Ú̯E¤Íªº¯SÂI©M¥i¶Qªº¦a¤è. 2012¦~12¤ë27¤é¯Î±Ò´f Globo H(GH) is a hexasaccharide specifically overexpressed on a variety of cancer cells and therefore, a good candidate for cancer vaccine development. To identify the optimal carrier and adjuvant combination, we chemically synthesized and linked GH to a carier protein, including keyhole limpet hemocyanion, diphtheroid toxoid cross-reactive material (CRM) 197 (DT), tetanus toxoid, and BSA, and combined with an adjuvant, and it was administered to mice for the study of immune response. Glycan microarray analysiss of the antiserum obtained indicated that the combination of GH-DT adjuvanted with £\-galactosylceramide C34 has the highest enhancement of anti-GH IgG. Compared with the phase III clinical trial vaccine, GH-KLH/QS21, the GH-DT/C34 vaccine elicited more IgG antibodies, which are more selective for GH and the GH-related epitopes, stage-specific embryonic antigen 3 (SSEA3) and SSEA4, all of which were specifically overexpressed on breast cancer cells and breast cancer stem cells with SSEA4 at the highest level (>90%). We, therefore, further developed SSEA4-DT/C34 as a vaccine candidate, and after immunization, it was found that the elicited antibodies are also IgG-dominant and very specific for SSEA4. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/10/25 ¤W¤È 12:33:51²Ä 27 ½g¦^À³
|
¥xÁÞ¥S¡G §Úªº½T¼g¿ù¤F¤@¶µ¡A¦ý¬O¸ò±z»¡ªº¤£¦P¡C §Úªºì¤å¡G¡u833¥Îªº¬O¥Õ³ïÃþ¬r¯À¡]DT¡^¡A¤£¬O¯}¶Ë·Ãþ¬r¯À¡]Toxoid¡^¡v À³×¥¿¬°¡G¡u833¥Îªº¬O¥Õ³ïÃþ¬r¯À¡]DT¡^¡A¤£¬O¯}¶Ë·Ãþ¬r¯À¡]Tetanus Toxoid¡^¡v http://www.sciencedirect.com/science/article/pii/S004101010700356X ¡uDiphtheria toxin (DT) ADP-rybosylates elongation factor-2 on a modified histidine residue called diphthamide, leading to a block in protein synthesis. CRM197 is a nontoxic DT mutant commonly used as a carrier for conjugate vaccines, and may have a potential as an anti-tumor agent¡K¡K.¡v ¥iª¾CRM197¨Ã¤£§t¯}¶Ë·¦¨¤À¡A³æ¯Â¥u§tDiphtheria¡ADT©Ò«ü¬°Diphtheria toxin¡C ¥«°âªºCRM197³W®æ¦p¬O»¡¡G https://www.mblintl.com/product/rk-01-515 ¡uThis Diphtheria toxin CRM197 was highly purified from growth media of Corynebacterium diphtheriae mutant CRM197.¡v ¡u¥Õ³ï¬r¯ÀCRM197¬O¥Ñ¥Õ³ï±ìµßÅܲ§®èCRM197ªº°ö¾i°ò°ª«×¯Â¤Æ¦Ó¨Ó¡C¡v ¤¤¬ã°|¤£¥i¯à¦Û¤v»s³yDT§a¡H¡]Corynebacterium diphtheriae¬O¥Õ³ï±ìµßªº¾Ç¦W¡^ ¨ä¹êµª®×´N¦b¯Î°|ªøªº½×¤å¤¤¡G¯»¶ê½×¤åªºSupporting Information¡]http://www.pnas.org/content/suppl/2013/01/25/1222649110.DCSupplemental/pnas.201222649SI.pdf#nameddest=STXT¡^ ²Ä7¦æ¡G ¡uDiphtheria toxoid cross-reactive material (CRM) 197 (DT) Protein and tetanus toxoid (TT) were purchased from Merck and Adimmune, respectively.¡v »¡©ú¤FCRM197ÁʦÛMerck¤½¥q¡A¦Ótetanus toxoid (TT)¯}¶Ë·Ãþ¬r¯ÀÁʦÛAdimmune¤½¥q¡]¥xÆWªº°ê¥ú¥Í§Þ¤½¥q¡^¡C ¨ìMerckºô¯¸§âCRM197²£«~»¡©ú¬d¥X¨Ó¡G ¡uhttp://www.merckmillipore.com/CA/en/product/Diphtheria-Toxin%2C-CRM-Mutant---CAS-92092-36-9---Calbiochem,EMD_BIO-322327 ¡v ¡uCRM₁₉₇ is a nontoxic diphtheria toxin that has a glycine to glutamic acid mutation at amino acid 52 in fragment A, resulting in the complete loss of enzymatic activity.¡v®Ú¥»¤£§t¯}¶Ë·¦¨¤À¡C ¦L¶H¤¤¥Õ³ï±ìµß¬O²£¥Í¥~¬r¯À¡]exotoxin¡^¡A¦Ó¯}¶Ë·¬OÃþ¬r¯À¡]toxoid¡^¡C ¡u¥~¬r¯À¸gºÖ°¨ªL©Î¥[¼ö³B²z¥i¦¨¬°Ãþ¬r¯À¡A¦ý¨ä¥L¯S©Ê¡A¦p§K¬Ì©Ê¤´³Q«O¯d¤U¨Ó¡C¡v ¡uA toxoid is a bacterial toxin (usually an exotoxin) whose toxicity has been inactivated or suppressed either by chemical (formalin) or heat treatment, while other properties, typically immunogenicity, are maintained.¡v¡]http://en.wikipedia.org/wiki/Toxoid¡^ ¤¤¤åªº¤j³°ºô¯¸¤]¦³¡G ¡u¥Î²Óµß²£¥Íªº¥~¬r¯À¡A¥[¤J¥ÒîǦZ¨ÏÅܬ°µL¬r©Ê¦ý¤´¦³§K¬Ì©Êªº¨î¾¯¡AºÙ¬°¡§Ãþ¬r¯À¡¨¡A¦p¯}¶Ë·Ãþ¬r¯À¡B¥Õ³ïÃþ¬r¯Àµ¥¡C²Óµßªº¥~¬r¯À¸g¥ÒîdzB²z¦Z¡A¥¢¥h¬r©Ê¦Ó¤´«O¯d¨ä§K¬Ìì©Ê¡A¯à¨ë¿E¾÷Åé²£¥Í«OÅ@©Ê§K¬Ìªº¨î¾¯¡C±`¥Îªº¥ÒîÇ·»²Gªº¿@«×¬O0.3¡ã0.4¢H¡C¥¦¥i¨Ï²Óµß¥~¬r¯Àªº¹q²üµo¥Í§ïÅÜ¡A«Ê³¬¨ä¦Û¥Ñ®ò°ò¡A²£¥Í¥Ò²m¤Æ¦Xª«¡]CH2=N-¡^¡C¨ä¥L°ò¹Î¡]¦p吲哚²§吡ÐüÀô¡^»P°¼Ã쪺Ãö¨t¥ç¥i§ïÅÜ¡A¦¨¬°Ãþ¬r¯À¡C¡v ¡]http://big5.wiki8.com/leidusu_101950/¡^ ©Ò¥HOBI-833©Ò§tªºDT¡A¤]´N¬O¡uDiphtheria toxoid cross-reactive material (CRM) 197 (DT)¡v¡A§Ú§ó¥[½T©w¬O¥Õ³ïÃþ¬r¯À¡Aµ´«D¯}¶Ë·Ãþ¬r¯À¡A¤]¤£§t¯}¶Ë·Ãþ¬r¯À¡C ¾ã²z¤@¤U¡G Toxoid ¬OÃþ¬r¯À¤£µ¥©ó¯}¶Ë·¡]Tetanus¡^¡AÁöµM¯}¶Ë·¬OÃþ¬r¯À¡A¡]¥Õ³ï¥~¬r¯À¤]¥i»s¦¨Ãþ¬r¯À¡^ ¹êÅç¬O±`¥Îªº§÷®ÆCRM 197¡A¤]´N¬ODT¡A¨Ã¤£§t¯}¶Ë·Ãþ¬r¯À¡A¯}¶Ë·Ãþ¬r¯ÀªºÁY¼g¬OTT¡]Tetanus toxoid¡^¡A¤¤¬ã°|´¿¦V¥xÆWªº°ê¥ú¥Í§Þ¤½¥qÁʱo¡C °|ªøì¤å¬O¡u¡K§â¥¦±µ¨ì³oÓ¡A³oÓdiphtheria toxin¡A³oÓ¬O¡A³oÓ¬O¡A³oÓ¬O¡]°±¹y¤@¤U¡^¯}¶Ë·ªº¬r¯Àªº¼Ë¤l¡K¡v¡]http://www.web.media.nthu.edu.tw/media/show/id/3905¡^ ¦b1:19:45³B °|ªø¯uªº¬O¤f»~¤F¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/10/24 ¤U¤È 09:55:15²Ä 26 ½g¦^À³
|
Cliff¤j: ¤£¹L°|ªø¦n¹³¤f»~¤F¤@¶µ¡A833¥Îªº¬O¥Õ³ïÃþ¬r¯À¡]DT¡^¡A¤£¬O¯}¶Ë·Ãþ¬r¯À¡]Toxoid¡^¡A¦b´X³õªººtÁ¿¤¤³£»~»¡¬°¡udiphtheria¡A¯}¶Ë·¡K¡v¡A¥i¯à¨S¤H´±ªÈ¥¿¥L§a¡H DT ¬O ¥Õ³ï¡B¯}¶Ë·²V¦X¬Ì] Diphtheria and tetanus toxoid childrens¡¦ dose Diphtheria ^¤å¬O¥Õ³ï tetanus ^¤å¬O¯}¶Ë· toxoid ^¤å¬OÃþ¬r¯À °|ªø¥Î^¤åÁ¿¥Xdiphtheria toxoid, ¥Î¤¤¤åÁ¿¥X¯}¶Ë·±ìµß¬r¯À , ¦]¨âÓ³£¦³Á¿¨ì, ¥i¯à¶¶§Ç¦³ÂI¶Ã,¤jP¤W°|ªø¨S¦³¿ù, 833¤£¬O¥u¥Î¥Õ³ïÃþ¬r¯À , ¬O¥Õ³ï¡B¯}¶Ë·Ãþ¬r¯À²V¦X¬Ì] D T ¸ê°T¨Ó·½: Google ·j´M ¬Ì]¤¤^¤å¦WºÙ¤Î²ºÙ¹ï·Ó¤@Äýªí ¥H¤W¨Ñ°Ñ¦Ò |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2014/10/24 ¤U¤È 06:07:50²Ä 25 ½g¦^À³
|
JM¤j¡A ¬O§Úµ§»~¡A¤p§Ì·N«ä¬O¡G¹F¤£¨ì"¤@"´Á¼Æ¾Úªº§QªÅªº¾÷²v¤]³vº¥°§C¤¤ µ½¤H¤j¡A ÁÂÁ±zªº¶K¤å¡A¤§«e¥i¯àº|¬Ý¤F¡Aì¨Ó15ºØÀù¤w¸g¦C¥X¨Ó(¨ÅÀù»P¤T³±©Ê¨ÅÀùÁÙ¬OÂk¤@ºØ¦n¤F)¡C Àù¯g·|¦p¤Ñªá¯ëµ´¸ñªº¥i¯à©Ê¡A¤p§Ì¤ñ¥ô¦ó¤H³£§Æ±æ³o¯à°÷¦¨¬°¤@Өƹê¡A¸òªÑ»ùµLÃö¡A¦³XXÓ¤ë¥H¤Wªº¤¤¦ì¼ÆPFS¤w¸g¬O°ê»Ú©Ê¤jÃÄ¡Aµ¥¤½¥¬¥X¨Ó¨ä©Ò±a¨Óªº°]´I¼Wªø¤p§Ì¤w¸gº¡¨¬¤F¡C¶i¤@¨Bªº¬ã¨s»P°Q½×¥u¬O¯Âºé¹ï¬ì¾Ç»P¥Í©Rªº¦n©_¡A«á¨Ó¾\Ūªº½×¤å©M±M§Q¤å³£¦³´£¨ìGlobo H-positive¡BSSEA-3-positive, SSEA-4-positiveµ¥ªº²ÓM¦Ê¤À¤ñªº·§©À¡A¦]¦¹¤p§Ì¤~·|¦³¹ïÁÞ¬ì¾Ç²£¥Í¤F·sªº¸àÄÀ¡C§_«h¥u¨Ì¨ÅÀù¤H¤fÂл\²v98%ªºì«h¡A¦Ó¤£ºÞ²ÓM¦Ê¤À¤ñªº·§©À¡A¤@´ÁÁ{§É¥u·|¦³¤G²Õ¼Æ¾Ú¡A¤@²Õ¬O¨S¦³GH¨t¦Cªº2% ©M²£¥Í¤£¤F§ÜÅ骺¤p¤ñ¨Ò±wªÌ¡A¥LÌ·|¦b´XӤ뤺´N´c¤Æ¡F¥t¥~¤@²Õ¬O98%¦©±¼²£¥Í¤£¤F§ÜÅ骺¤Ö¼Æ¤H¡A¥L̪º¤ñ¨ÒÀ³¸Ó¦û80%©Î¬Æ¦Ü§ó°ªªº¤ñ¨Ò¡A·|¦³»·¤j©ó¤T¤Q´XÓ¤ë©Î»·¤j©ó4¦~ªºPFS(²z½×¤WÀ³¸Ó»¡·|¦³µL¤jªºPFS ¡A¦]¬°Àù²ÓM©MÀù·F²ÓM³£®ø·À¤F¡A¤£·|¦A´c¤Æ¤F)¡A·Ó²z½×¡A³o¤@²Õ·¥°ª¤ñ¨Òªº±wªÌ¨ì²{¦bY¤£¬O¦Ñ¤Æ¦º¤`À³¸Ó¥þ³¡³£ÁÙ¬¡µÛ¡A¦ý¤@´Á¥O¤HÅåÆvªº¼Æ¾Ú¨Ã¨S¦³±µªñ¨ì²z½×ªºµ²ªG¡C ©µÄò¥H¤Wªº±À½×¡A¤T´Áªº¼Æ¾Ú¤@©w¤ñ¤@´Á¦n¡A¦]¬°¥[±j¤F822ªº¬I¥´¾¯¶q¡AIgM©M IgGªº§ÜÅé¶q¸û¦h¡A²z½×¤W¹êÅç²Õªº±wªÌ°£¤F²£¥Í¤£¤F§ÜÅ骺¤H¥~¡A²{¦b¤£·|¦³¥ô¦ó¤@Ó·|´c¤Æ¡A¦]¦¹§Y¨Ï¨ì©ú¦~4¤ë¸Ñª¼¡A¹êÅç²Õ¤]¤£·|¦³¤¤¦ì¼ÆªºPFSªº¼Æ¾Ú¡A©¡®É¥u¤½¥¬228¤Hªº¹êÅç²Õ¤¤¦³10%©Î20%´c¤Æ¡A¨ä¾l80%©Î90%¥H¤Wªº±wªÌ²z½×¤W¤£·|¦A´c¤Æ¤F¡C ¤£¹L¡AÃö©ó¨ì©³¬O¤°»ò¦]¯À¨Ï±o¤w¬I¥´822¥B²£¥Í§ÜÅ骺¤j¦h¼Æ±wªÌ·|¦³¤£¦PªºµL¯e¯f¶i®i´c¤Æ´Á¡A¶i¦Ó²£¥Í¤F¦¹¹êÅç²Õªº¤¤¦ì¼ÆPFS¡A³oÂI¤£¥ÎÄ~Äò°Q½×¡A¸Ñª¼¤F«á¡A±i¸³·|§i¶D§Ú̵ª®×¡A¤p§Ì¥u¬O¦n©_¥h´¢·Q¨ä¤¤¥i¯àªºì¦]¡C Cliff¤j¡A §Ú¦³¬Ý¨ì±z»¡ªº¡A·Ó¤å¦rªº»¡ªk¡AÁÞ´¹¤ù¨Ó§@Àù¯g¶EÂ_ªºcriteria¬O¦³¬YÓ¨î½d³òªº¡A¤p§Ì¬Ý¤§«eªº2008½×¤å©M2012±M§Q¤å©Ò¬ã¨sªº53ÓÀËÅéùØ¡AGlobo H-positive¡BSSEA-3-positive¥æ¶°ªº¤ñ¨Ò·¥°ª¡A¦]¦¹¥H¨ÅÀù°µ¨Ò¤l¡A60%¥H¤Wªº¤H¤fÂл\²vÀ³¸Ó¨S°ÝÃD§a¡C |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2014/10/24 ¤U¤È 05:26:24²Ä 24 ½g¦^À³
|
¯Î°|ªø±q¤@Ó¥¼ª¾ªºÁÞ¤À¤l¥@¬É,¤@ÀY®â¤J¶W¹L30¦~¦Ó.±i©À·O¸³¨Æªøªº²´¥ú¤]¤w¬Ý¨ì10¦~20¦~¥H«áªº¨Æ(¥Í§Þ±N¨Ó¥²¶·¨«¨ÖÁʸô½u),¥i¨£¥L̪º®æ§½¬Ýªº°÷¤j°÷»·°÷¤[,¦U¦ì¯E¤Í¦pªG¤]¥H¥L̪ººë¯««ù¦³¯E¹©,µu½u®¶ÀúÄAð´N¤£·|ÀY·w¤F. |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2014/10/24 ¤U¤È 04:30:14²Ä 23 ½g¦^À³
|
¤H¦]¹Ú·Q¦Ó°¶¤j¡A¯Î°|ªø¬O¡A±i¸³¬O¡A¤¨¦ÑÁó¤]¬O¡A¦U¦ì¦º©¾ªº¯E¤Í¤]¬O¡A§Æ±æ¦³´Â¤@¤éOBI·sÃĦ¨¬°¥xÆW¤§¥ú~~ ¸`¿ý¦Û¬ì¾Ç¤HÂø»x¡G http://sa.ylib.com/MagCont.aspx?Unit=featurearticles&id=1248 ÁöµM¬ã¨s¤F¤K¦~ªº³J¥Õ½è¤Æ¾Ç¡A¦ý¯Î±Ò´f»{¬°³oÓ»â°ì¤w¸g³vº¥¦¨¼ô¡AÄ~Äò°µ¤U¥h¤]¨S¤°»ò¾÷·|Àò±o«¤j³Ð·s¬ð¯}¤F¡C¥Lª¾¹DMIT¤Æ¾Ç¨t±Ð±ÂÃh¯SÁɯ÷¡]George Whitesides¡^¥¿¦b¬ã¨s»Ã¯À¦³¾÷¦X¦¨¡A±N¨Ó¥i¯à¥i¥HÀ³¥Î¦b½ÆÂø¤À¤l¡]¥]¬AÁÞ¤À¤l¡^ªº¬ã¨s¤W¡A´N¨M©w¸òµÛÃh¯SÁɯ÷¡A¬ã¨s¥H»Ã¯À¬°¥Dªº·s¤Æ¾Ç¦X¦¨ªk¡C ¯Î±Ò´f¨ì¤FMIT¤~¯u¥¿½T»{¦Û¤vªº¿³½ì¡A©ó¬O©]¥HÄ~¤é¦a¤u§@¡A³s°²¤é³£¶i¹êÅç«Ç¡C¥L»¡ÁöµM·í®É¨Åé·Pı«Ü¯h¡A¦ý¤ß±¡«o«Ü¤®¾Ä¡A§Æ±æ»°§ÖÀò±o¦¨ªG¡F¤@¥¹¦³·sµo²{¡A§óı±o¤@¤Á³£È±o¤F¡C¥L¥u¥Î¤F¤T¦~´NÀò±o³Õ¤h¾Ç¦ì¡A쥻¸Ó¦^¨ì¤¤¬ã°|¼i¦æ¯d¾¯dÁ~ªº«´¬ù¡A¦ý¤¤¬ã°|è¦n¨S¦³Â¾¯Ê¡A·í®É¥xÆWªº¤j¾Ç¤]¨S¦³¥Í¤Æ¬ì¾Ç©Ò³Õ¤h¯Z¡A¦]¦¹¥L¨M©w¯d¦b¬ü°ê¡C¤ý¥úÀ鬰¤FÄU¥L¦^¥x¡A¯S¦a¸¥h¬ü°ê¡A¦ýÅ¥¤FÃh¯SÁɯ÷ªº¤@®u¸Ü¡G¡u¯Î±Ò´f¦pªG¯d¦b¬ü°ê¡A·|¦¨¬°¤£±o¤Fªº¤j¾ÇªÌ¡C¡v¤~¥´®ø©ÀÀY¡C¯Î±Ò´fÁÙ¬°¦¹½æ±¼¥x¥_ªº©Ð¤l¡A§â¤T¦~ªºÁ~¤ôÁÙµ¹¤¤¬ã°|¡C ¥Ñ©óÁÞ¤À¤lªº°ª«×½ÆÂø©Ê¡]¨£50¶¡q½ÆÂøªºÁÞ¤À¤l¡r¡^¡A¬ì¾Ç®a¤ñ¸û¤Öªá¤ß¤O¦b¤W±¡A¦Ó±Mª`©óDNA¡B³J¥Õ½èªº¬ã¨s¡C¦ý¤HÅ餺¦³90%¥H¤Wªº³J¥Õ½è³£©MÁÞ¤À¤l³s±µ¦b¤@°_¡A§Î¦¨ÁÞ³J¥Õ¡A¯Î±Ò´f»{¬°¨ä¤¤¤@©w¦³¹D²z¡A¥u¬OÁÙ¨S¦³¤Hª¾¹D¡A©ó¬O¥L¨M©w¿ï¾ÜÁÞ¤À¤l°µ¬°¬ã¨sÃD¥Ø¡A¦]¬°³o¬OÃöÁä°ÝÃD¡A¥un¸Ñ¶}Á¼¹Î¡A´N¥i¥H¶i¤J¥þ·sªº»â°ì¡C¦Ü©ó§xÃø«×¡Aˤ£¬O¥L¦b·Nªº°ÝÃD¡A¥L»¡¬ã¨s¤u§@±¹ïªº´N¬O¡u¥¼ª¾¡v¡A¡u§Úªº¤j³¡¥÷¬ã¨s³£¥¢±Ñ¡A¦ýÁ`·|¦³·s¤è¦V¥X¨Ó¡A¥i¥H¶i¦æ¤U¤@¨B¬ã¨s¡C¡v ¯Î±Ò´f¦b¼w¦{¹A¤u¤j¾Ç¥|¦~§Y¤É¬°¥¿±Ð±Â¡A1989¦~À³¥v¤¦¦ò¤j¾Ç¤§¸u¾á¥ô±Ð±Â¡A¦b«e©¹¥[¦{¬ÝÀô¹Òªº¦^µ{¡A¶¶¹D¥h¸t¦a¤úôªº´µ§J¨½´¶´µ¬ã¨s°|ºtÁ¿¡AºtÁ¿¤@µ²§ô¡A°|ªø´N´£¥X¤@¥÷±ø¥óÀu´ìªº¦X¬ù¡A§Æ±æ¸u½Ð¥L¾á¥ô·s¦¨¥ßªº¤Æ¾Ç¨t¥D¥ô¡C¯Î±Ò´f¦Ò¼{¨ì´µ§J¨½´¶´µ¬ã¨s°|¦b¥Íª«Âå¾Ç»â°ì«D±`ª¾¦W¡AÁöµM¨S¦³¬ã¨s¤Æ¾Çªº¸gÅç¡A¦ýÀ³¸Ó«Ü¦³¼ç¤O¡A´N¨M©w¨ü¸u¡A¦ý°û©Ú¦æ¬F¾¡A¥uÄ@·N·íÁ¿®y±Ð±Â¡A±M¤ß±q¨Æ¬ã¨s¡C ¯Î±Ò´f¦b´µ§J¨½´¶´µ¬ã¨s°|«Ý¤F14¦~¡A³vº¥¸Ñ¶}ÁÞ¤À¤lªº¯µ±K¡C¥Lµo©úªº¡u¤@Á禡»Ã¯À¤ÏÀ³¡v¡A¬Oº¦¸±Ä¥Î¥Íª«¤èªk¦X¦¨½ÆÂøªºÁÞ¤À¤l¡A¦Ó¥B¨ì²{¦b¬°¤î¡A¤´¬O°ß¤@¥i¤j¶q¦X¦¨¹èÁÞªº¤èªk¡C ¤HÅé²ÓMªí±ÁÞ³J¥Õ¤WªºÁÞ¤À¤l¬O¹èÁÞ¡A¨C¤@ºØ¹èÁÞ¤¤ªº¦UÓ³æÁÞ¦³¨ä¯S®í³s±µ¤è¦¡¡AY³s±µ¤è¦¡¿ù»~¡A´NµLªk¦¨¬°¥¿½Tªº¹èÁÞ¡C¦ÛµM¬É¬O¥Î»Ã¯ÀÅý³æ¿}µ²¦X¬°¹è¿}¡A¯Î±Ò´f¼Ò¥é¤ÑµMªº¦X¦¨ªk¡A¥ý¹ý©³¤F¸Ñ»Ã¯À»P³æÁÞ¤§¶¡ªºÃöÁp©Ê¡AµM«á§ä¥X¾A·í»Ã¯À¨Ó¬¡¤Æ³æÁÞ¡A¦A¥Î¥t¤@ºØ»Ã¯À±N¤w¬¡¤Æªº³æÁÞ³s±µ°_¨Ó¡A³o¼Ë¥un±N¥¿½Tªº³æÁÞ©M»Ã¯À³£©ñ¶i¤@ÓÁç¤l¸Ì¡A´N¥i¦X¦¨©Ò»Ýªº¹èÁÞ¡C ³oºØ¥Î»Ã¯À¦X¦¨ªº¤è¦¡¡AÁö¥i¤j¶q¦X¦¨¡A¦ý¨ä§xÃøÂI¦b©ó¤£©ö¨ú±o¨¬°÷¦hºØªº»Ã¯À¨Ó¦X¦¨¥þ³¡¥i¯àªº¤ÑµM²£ª«¡A¨Ã¥BÃø¥H¦X¦¨¥X«D¤ÑµMªº²£ª«¡C¦]¦¹¯Î±Ò´fµo©ú¤F¥t¤@®M¡uµ{¦¡¤Æ¤@Á禡¦hÁÞ¦X¦¨ªk¡v¡A¥Î¤Æ¾Ç¦Ó«D¥Íª«¤èªk¨Ó¦X¦¨¹èÁÞ¡A¥i¥H¦X¦¨¥ô¦ó¤@ºØ¤ÑµM©Î«D¤ÑµMªº¹èÁÞ¡AÁöµM¶q¤£¤j¡A¦ý¤w¨¬°÷¶i¦æ«áÄò¹êÅç¡C ¥H¶Ç²Î¤Æ¾Ç¤è¦¡¦X¦¨¯S©w¹èÁޮɡA¥²¶·¥ý±N¨C¤@³æÁÞ¤À¤l¤W¤£»Ý§@¥Îªº³s±µÂI¥Î«OÅ@°ò¡u¸n¡v°_¨Ó¡A¥u¯d¤U¥i¤ÏÀ³ªº³s±µÂI¡AÅý¨âÓ³æÁÞµ²¦X¦¨ÂùÁÞ¡A¦p¦¹¤ÏÂоާ@¡A¤~¯à±o¨ì©Ò»Ýªº¹èÁÞ¡A¹Lµ{«D±`Ác½Æ¡A¦X¦¨¤@ºØ¹èÁÞ¬ù»Ý1~2¦~®É¶¡¡C¡K |
|
|
·|û¡G¤p±¶10135877 µoªí®É¶¡:2014/10/24 ¤U¤È 04:19:38²Ä 22 ½g¦^À³
|
180¤¸ªº¦¨¥»,¬O¤@¦~«eªº¨Æ§a |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/10/24 ¤U¤È 04:10:23²Ä 21 ½g¦^À³
|
¨ÅÀù¡BªÍ¡B¨x¡B¤j¸z¡B¤fµÄ¡BG¡B¯ØŦ¡B¸£¡B¹¹D¡BµÇŦ¡BÄáÅ@¸¢¡B§Z±_¡B¤l®cÀV¡B¤l®c¤º½¤¡B¤T³±©Ê¨ÅÀù©MÁxÅn¡C©Ò¥H¨ÅÀù»P¤T³±©Ê¨ÅÀù³Q¦C¬°¨âºØ¡H ³o¤@¬q¤]¦³¡]http://www.worldjournal.com/view/full_van/25467608/article-%E6%9C%AA%E4%BE%86-%E6%89%931%E7%A8%AE%E7%96%AB%E8%8B%97-%E9%98%B216%E7%A8%AE%E7%99%8C%E7%97%87?instance=bc_bull_left1¡^ ¤£¹L°|ªø¦n¹³¤f»~¤F¤@¶µ¡A833¥Îªº¬O¥Õ³ïÃþ¬r¯À¡]DT¡^¡A¤£¬O¯}¶Ë·Ãþ¬r¯À¡]Toxoid¡^¡A¦b´X³õªººtÁ¿¤¤³£»~»¡¬°¡udiphtheria¡A¯}¶Ë·¡K¡v¡A¥i¯à¨S¤H´±ªÈ¥¿¥L§a¡H ¤p©_¤j¤£ª¾¦³¨S¦³ª`·N¨ì¡A868ªº±M§Q¤å¥óùØ¡AWhat is claimed is¡G¡]Án©ú©Ò¦³Åv¡^ùئ³¤@¬q±Ôz¡G wherein the cancer is both Globo H-positive and Gb5-positive; and a higher ratio of the amount of Globo H-bound, Bb2-bound, Bb3-bound, or Bb4-bound antibodies to the amount of Gb5-bound antibodies, as compared with that of a cancer-free subject, indicates that the subject has the cancer. ¬O¤£¬O©w¸q¤F¦p¦ó¥HÁÞ´¹¤ù¨Ó§@Àù¯g¶EÂ_ªºcriteria¡HGH(+)&Gb5(+)&»P¥¿±`¤H¤ñ¸ûªº§ÜÅé¤ñÈ¡A¤T¶µ¦@¦P¨Ó½×©w¡H |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2014/10/24 ¤U¤È 03:42:39²Ä 20 ½g¦^À³
|
¥Í¬¡¤¤¤ß¡þºî¦X³ø¾É ¯Î±Ò´f¡G¨ÅÀù¬Ì]Y¦¨¥\¡@¥¼¨Ó¥i¨¾16ºØÀù ¬Ì]¥i¹w¨¾«Ü¦h¯e¯f¡A¦ý¦ì©~°ê¤H¤Q¤j¦º¦]º¦ìªºÀù¯g¦Ü¤µ«oµLªk¥H¨Æ¥ý¬I¥´¬Ì]§K¬Ì¡C¤£¹L¡A¤¤¬ã°|°|ªø¯Î±Ò´f¦b19¤é®i¶}ªº¡u2014«Ø±d°ª®p½×¾Â¡v¤Wªí¥Ü¡A ¥Lªº¬ã¨s¹Î¶¤¥¿¦b°w¹ïÁÞ¤À¤l¨ÅÀù¬Ì]¶i¦æ²Ä¤T´ÁÁ{§É¹êÅç¡A¡u¦pªG¦¨¥\¡A¥¼¨ÓÀù¯g¥i¯à·|¦p¤Ñªá¯ëµ´¸ñ¡v¡C ³o³õ½×¾Â¬O¥ÑÁp¦X³ø¤Î¤¤¬ã°|©ó19¡B20¤éÁ|¿ì¡AÁܽФF¦h¦W«¶q¯Å¾ÇªÌ»P¥Á²³¤À¨ÉÀù¯g³Ì·s¬ã¨s¡A§Æ±æ¥Á²³¯à³z¹L³o³õ½×¾ÂÁA¸Ñ§ó¦h¨¾Àùªºª¾ÃÑ¡C ¯Î±Ò´f¬Q¤Ñ¦¤W°w¹ï¤k©Ê°·±d³Ì¤j±þ¤â¡u¨ÅÀù¡v¶i¦æ±´°Q¡A¥L¥H¡u¬Ì]®Úªv¨ÅÀù ¥¼¨Ó¤£¬O¹Ú¡v¬°ÃD¡Aµoªí¬ã¨sªº³Ì·s¶i®i¡C ¯Îªí¥Ü¡A¦Û¤v»P¬ã¨s¹Î¶¤µo²{¨ÅÀù²ÓM¤W¡A¦³3ºØ¯S®íªºÁÞ¤À¤l¬O¥¿±`²ÓM©Ò¨S¦³ªº¡A©ó¬O¥LÌ¥H³o3ºØÁÞ¤À¤l¬°°ò©³³]pÀù¯g¬Ì]¡A¬Æ¦Ü³z¹L»Ã¯À¶q²£³oÃþÁÞ¤À¤l¡A ¥Ø«e²Ä¤@¥N¬Ì]¤w»P¥x¤jÂå°|°t¦X¡A°w¹ï342¦W¨ÅÀù±wªÌ¡A¹j3©P¬I¥´¤@¦¸¬Ì]¡A¾ãÓÀøµ{¦@»Ý¬I¥´9°w¡A¹wp¥b¦~§¹¦¨ªvÀø¡C(µù: À³¸Ó¬O9Ӥ맹¦¨ªvÀø) ¯Î±Ò´fÁÙ±j½Õ¡A°£¤F¨ÅÀù²ÓM¥~¡A³o3ºØ¯S®íªºÁÞ¤À¤lÁÙ¥i¦bªÍ¡B¨x¡B¤j¸z¡B¤fµÄ¡BG¡B¯ØŦ¡B¸£¡B¹¹D¡BµÇŦ¡BÄáÅ@¸¢¡B§Z±_¡B¤l®cÀV¡B¤l®c¤º½¤¡B ¤T³±©Ê¨ÅÀù©MÁxÅnµ¥Àù²ÓM³B§ä¨ì¡A¥¼¨ÓY¬Ì]¬ãµo¦¨¥\¡A¤£¥u¯à¹ï¨ÅÀù²£¥Í¦³®Ä§ÜÅé¡A´N³s¤Wzªº15ºØÀù¯g¤]·|¦]¦¹µ´¸ñ¡C (µù: "µ´¸ñ", ¬O§_¤Ó²z·Q¤Æ? ¤£¹LÁÙ¯uªº§Æ±æ"µ´¸ñ"¯à¹ê²{, ¯Î°|ªø¤]±N¦¨¬°¾ú¥v¤W³Ì°¶¤jªº¬ì¾Ç®a!?) -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ¯Î°|ªø»¡: Globo H-KLH/QS21(OBI-822/821)©MGlobo H-DT/C34(OBI-833/832)²£¥Íªº IgM©M IgG§ÜÅé³£¯à®ø·À±a¦³Globo H, SSEA-3, SSEA-4ªºÀù²ÓM©MÀù·F²ÓM. ¦]¦¹¥unÀù²ÓM©MÀù·F²ÓM±a¦³Globo H©ÎSSEA-3©ÎSSEA-4ªºÀù¯g, OBI-822©ÎOBI-833¥´¤JÀù¯g±wªÌÅ餺, ¥un±wªÌªº§K¬Ì¥\¯à¥¿±`, ¯à²£¥Í¨¬°÷ªº IgM©M IgG§ÜÅé¶q, ´N¯à±NÀù²ÓM©MÀù·F²ÓM®ø·À. °£¤F¤Wzªº16ºØÀù¯g¥~, ¨ä¥¦ªºÀù¯g¬O§_¤]±a¦³Globo H©ÎSSEA-3©ÎSSEA-4©O? £«¬Â¤j, ±zªº¨º¦ì¿Ë±Âå¥Í, ¤]¬OªÑ¥«°ª¤â, 180¤¸ªº¦¨¥», ¸g¹L´X¦¸¤j°_¤j¸¨, ³£¨S¦³³Q¬~±¼, ¥i¨£¥L¬O¬Ý¦nOBI-822ªºÀø®Ä©M¯E¹©ªº«e´º. |
|
|
·|û¡GJM10139061 µoªí®É¶¡:2014/10/24 ¤U¤È 03:32:22²Ä 19 ½g¦^À³
|
To ¤p©_¤j ³Ì«á¤@¥y¬O§_¬O: ¹F¤£¨ì"¤@"´Á¼Æ¾Úªº§QªÅªº¾÷²v¤]³vº¥°§C¤¤ Thanks. |
|
|
·|û¡Gkenken10138351 µoªí®É¶¡:2014/10/24 ¤U¤È 03:16:39²Ä 18 ½g¦^À³
|
«Ü¦h±wªÌ²{¦b·Q¥[¤J¹êÅç³£¨S¿ìªk¤F,¯u§Æ±æ§ÖÂI¤W¥«,¹Å´f³o¨Ç¯f¤Í. |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2014/10/24 ¤U¤È 01:56:32²Ä 17 ½g¦^À³
|
¤@¦ì¿Ë±è¦n¬O°ü¬ì¥D¥ô,¤]¦³°Ñ¥[obi-822¨ÅÀùÁ{§É.¥L¥u»¡Àø®ÄÀ³¸Ó«Ü¦n,·|¤£·|¦¨¥\¤]¨S§â´¤.¥L¦b180¤¸¤]¶R8±i¤U¦¸¸I¨ì¥L¦A°Ý¥J²Ó. |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2014/10/24 ¤U¤È 01:47:46²Ä 16 ½g¦^À³
|
Cliff¤j¡AFaith¤j¡A¦U¦ì¤j¡A ¦pªG¨üÀ˪̤£¬O¦bGlobo H¦³Ãöªº¨º16ºØÀù¯g¤º¡A¦³¨S¦³®Ä¡H¡]·Ó¤º¤åªº±Ôz³s¥Ö½§Àù¡B¯«¸g¥À²ÓM½F³£¦C¤J¤F¡K¡K¡^ ³o°ÝÃD¥i¯à§ä¨ìµª®×¤F¡A¦ý¤p§Ì¤£¯à§¹¥þ½T©w¡A¦³¿ù»~ªº¦a¤è½Ð«ü¥¿¡C Cancer types can be grouped into broader categories. The main categories of cancer include: ¡PCarcinoma - cancer that begins in the skin or in tissues that line or cover internal organs. There are a number of subtypes of carcinoma, including adenocarcinoma, basal cell carcinoma, squamous cell carcinoma, and transitional cell carcinoma. ¡PSarcoma - cancer that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. ¡PLeukemia - cancer that starts in blood-forming tissue such as the bone marrow and causes large numbers of abnormal blood cells to be produced and enter the blood. ¡PLymphoma and myeloma - cancers that begin in the cells of the immune system. ¡PCentral nervous system cancers - cancers that begin in the tissues of the brain and spinal cord. ¤j³¡¥÷ªºÀùºØ¬O¤W¥Ö²ÓM(epithelial cells)ªºÀù¡A¤W¥Ö²ÓMªºÀùºÙ¤§¬°carcinoma¡A¬ù¦³85%ªºÀù¬Ocarcinoma¡A¥t¥~°©²Õ´¡B¦Ù¦×¡A¦åºÞ¡B¦å²G¡A²O¤Ú¡B¯«¸g¨t²Îªº²ÓM©Ò§Î¦¨ªºÀùºØ´N¤£¬O¤W¥Ö²ÓMªºÀù¡C±M§Q¤å¤¤´£¨ì¡A¥un¬O¤W¥Ö²ÓM¬ÛÃöªºÀù³£¥i¾A¥ÎÁÞ´¹¤ùªºÀùÀË´ú¤èªk¡A¦]¦¹¦³85%ªºÀù³£¬O¦³®Äªº¡C¥Ö½§Àù©M¶Â¦â¯À½F(¥Ö½§Àùªº¤@ºØ¡A³Ì´c©Êªº¥Ö½§Àù)¡A½T©w¬O¤W¥Ö²ÓM§Î¦¨ªºÀù¡A©Ò¥HÁÞ´¹¤ù¥i¥HÀË´ú¡A¯«¸g¥À²ÓM½F¤p§Ì¤£½T©w¡C Globo H¦³Ãöªº¨º16ºØÀù¯g¡A¨ì©³¦³¨S¦³¥]§t¥Ö½§Àù©M¶Â¦â¯À½F¡A¨ì¥Ø«e¤p§Ì¤´¥¼¬Ý¨ì§¹¾ãªºÃ¹¦C16ºØÀù¡A¦pªG¦³¡A¨ºªvÀø»PÀË´úªº16ºØÀù¬O¤@Pªº¡F¦pªG¨S¦³¡A¨º°£¤FªvÀøªº16ºØÀù¥~¡A¥t¥~¦³¤@¨Ç¤W¥Ö²ÓMªºÀù¤£¦b822©Î833ªºªvÀø½d³ò¡A¦ý¤´¥i¥ÎÁÞ´¹¤ùÀË´ú¥X¨Ó¡C¦Ü©ó¬°¦ó¥Ö½§Àù©M¶Â¦â¯À½F¬O¤W¥Ö²ÓMªºÀù¡A«o¤£¦b¥i16ºØÀùªºªvÀø½d³ò¡A¬O¤H¤fÂл\²v¤Ó§C¡H©ÎªÌÀù²ÓM¦Ê¤À¤ñ¤Ó§C¡H¤S©ÎªÌ¨ä¥¦ì¦]¡H Faith¤j¡A±q¥H¤W±À½×¡AÁöµM¤p§Ì¥H¬°NED¤£¬O¹êÅç²Õªº´¶¹Mµ²ªG(²ÓM¦Ê¤À¤ñ¥i¥H¸ÑÄÀ)¡A¦ý°Ñ»P¹êÅ窺¨ÅÀùÂಾ±wªÌ©ÒÂಾ¨ì¨ä¥L³¡¦ìªºÀù²ÓM¡A²z½×¤W¨ä¥»½è©M쥻ªº¨ÅÀù²ÓM¬O¬Û¦Pªº¡A³o¸ò¤@¶}©l¶EÂ_¥X¬O¸£Àù©Î°©ÀùªºÀù±wªÌ©Ò§Î¦¨ªºÀù²ÓM¬O¤£¤@¼Ëªº¡A¨ÅÀù²ÓM¸g¥Ñ¦å²G©Î²O¤ÚÂಾ¨ì¨ä¥L³¡¦ì¡A822²£¥Íªº§ÜÅé¦b¨Å©Ðªº¸~½F¦³®Ä¡A¦b¨ä¥L³¡¦ì¤]·|¦³®Ä¡A¦]¦¹´N³v¨B¦¬´_¥¢¤g¡AÅܦ¨NED¤F¡C¦Ó822©Î833¥u¹ï¤W¥Ö²ÓMªºÀù¦³®Ä¡A¹ï¸£Àù©M°©Àù¬OµL®Äªº¡A¦]¦¹ÀùºØªº¿ï¾ÜnÂÔ·V¡C «¢¡A¶}ª±¯ºªº¡AÁȨì¤F°]´I¡A°·°·±d±dªº¥Í¬¡¤~¬O¯uªº¡A«D¨ì¸U¤£±o¤w¡A¤~¥h¥Î¨ì¯E¹©ªº²£«~¡C ¯E¹©²{¦b³Ì¤jªº§Q¦h¬O©ú¤Ñ«Å¥¬´Á¤¤¤ÀªR¡A¬°¦ó¬O§Q¦h¡H¦]¬°n¥Î²Îp¤èªk¨Óµý¹êÁöµM¤w¹F¨ì171¤H¤F¡A¦ýÃĮīܦn¡A¤w¸g¹F¨ì¤FXXӤ몺¤¤¦ì¼ÆPFS¡A³oXXÓ¤ë¤w¸g¬O°ê»Ú©Ê¤jÃĤF¡A¤£¬Û«Hªº¤H¬Ý¤F¼Æ¾Ú¤]±o¬Û«H¡AªÑ»ù·|«ç»òªí²{´N¥Ñ¦U¦ì¨Ó·Q¹³¡F¯E¹©²{¦b³Ì¤jªº§QªÅ¤]¬O©ú¤Ñ«Å¥¬´Á¤¤¤ÀªR¡A¬°¦ó¬O§QªÅ¡H¦]¬°²Îp¤ÀªR«á¡A¤T´Áªº¤¤¦ì¼ÆPFS¼Æ¾ÚÀ³¸Ó¹F¤£¨ì¤@´Áªº¨º»ò¦n¡A©Î³\¤£¤Ö¯E¤Í·|·P¨ì¥¢±æ¡C ¨º¦pªGÁÙ¤£«Å¥¬´Á¤¤¤ÀªR©O¡H´N¬O³Ì¤jªº§Q¦hÁÙ¨£¤£¨ì³»¡A¦Ó¹F¤£¨ì¤T´Á¼Æ¾Úªº§QªÅªº¾÷²v¤]³vº¥°§C¤¤¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/10/24 ¤U¤È 01:38:12²Ä 15 ½g¦^À³
|
§Ú»{¦P¤p©_¤j»¡ªº¡uÃø¹D¥¿±`¤H°¸º¸¤]·|¥X²{Àù²ÓM¡A³o¨ÇÀù²ÓM¤]¦ñÀHµÛ¢Õ¢Ö¤@°_µo®i¡A¦ý¦bªì´Á´N³Q±j¤jªº§K¬Ì¨t²Îµ¹Äè·À¤F¡A©Ò¥H¤´ºû«ù¨Å骺°·±d¡v¡A©Ò¥H¹L³Ò¡B¡B¦ÑÁÚ¡A¦Y¶i¤Ó¦hªºPÀùª«©Î¬r¯Àµ¥µ¥¤£§Q°·±dºûÅ@ªº°Ê§@¡A³£¥i¯à¥¢¥h¦Û§Ú×´_ªº¯à¤O¡A¼W¥[¿©Àùªº¥i¯à¡C Faith¤j¡A±zªº°ÝÃDµ¥822Àø®ÄªºÁn¦W¶Ç¶}¤§«á¡A¤@¨Ç¶åı±Ó¾Uªº¨p¥ßÂå¾Ç¤¤¤ß¥i¯à´N·|¼¯®±À¿´xÅDÅD±ý¸Õ¤F¡A¦A¤£µM¡A©ßÓ°T®§§ä¦ì¤º¬ì¡]¤£¬O¤º´ò¬ì¾Ç¶é°Ï³á¡^ªº¯E¤Í¡A¹ï822¤ñ¸û¤F¸Ñ¡A¦b¤£¹H¤Ïªk¥Oªº±¡§Î¤UÀ³¸Ó¥i¦æ¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/10/24 ¤W¤È 07:57:05²Ä 14 ½g¦^À³
|
¤p©_¤j §Ú°O±o¤é¥»ªºª÷»È±C±CÓ¬¡¨ì107.108·³ ¥L̪º¦º¤`¬Ò«D¦]Àù¯g,¦ý«á¨Óµo²{,Å餺¬Ò¦³¦h«Àù²ÓM §Ú³Ìªñ¦b·Qªº¤@Ó°ÝÃD¬O ©Ò¿×ªºNED(No Evidence of Diseases) À³¸Ó¬O«ü¦bÅ餺¤wµL´c©Ê¸~½F ¦³½ìªº¬O ¯E¹©¥Ø«e¦b¥xÆW2.3´Á»P¬ü°ê2´ÁªºÁ{§É ¦¬ªº®× ¥²¶·¬O¨ÅÀù¨ÃÂಾ¨ì¨âÓ¾¹©x¥H¤W ¨ÅÀù³Ì±`¨£ªº¬OÂಾ¨ì¨x.ªÍ.¸£.°© ¨º»ò´N¥Nªí°£¤F¨ÅÀù¥~,ÂಾªºÀù¤]NED¤F ©Ò¥H§Ú¤@ª½¦n©_ Y¯E¹©¥¼¨Ó¥xÆWªº822ÃĤW¥«¤F °²³]§Ú¦Û¤v©Î§Ú¦³¿ËªB¦n¤Í±o¤F¨x.ªÍ.¸£.°©¨ä¤¤¤@¶µ(4ºØ´N¦n¤£¥Î¨ì16ºØ) ³o¤@¸s¤H¥i¥H"¦Û¶O"¥´822ªºÃĶÜ? ·|³o¼Ë°Ý¬O¦]¬°¦³¨ÇÃįf¤H·Q¦Û¶OÂå¥ÍÁÙ¤£¨£±o·|µ¹©Î·Qµ¹(Âå¥Í¦³¨ä±M·~¦Ò¶q) ¦pªG¥i¥H.....«z~~¦Û¤v·Q¹³ «¢«¢«¢ (¦Ñ¬O³ßÅwJ«ä¶Ã·Q,¼ç¨S¨â¤Ñ´N¥X¨Ó¤F,«¢«¢«¢....) ¸É¥R:¹Ç¤j,§Aªº¦W¦r¨úªº¯u¦n,§Ú¤]n§â¯E¹©Åó¨c¨c |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2014/10/24 ¤W¤È 12:08:05²Ä 13 ½g¦^À³
|
Cliff¤j¡A¦U¦ì¤j¡A .¦pªG¨üÀ˪̤£¬O¦bGlobo H¦³Ãöªº¨º16ºØÀù¯g¤º¡A¦³¨S¦³®Ä¡H¡]·Ó¤º¤åªº±Ôz³s¥Ö½§Àù¡B¯«¸g¥À²ÓM½F³£¦C¤J¤F¡K¡K¡^ §Ú¬Ý±M§Q¤å¤¤´£¨ì¡A¥un¬O¤W¥Ö²ÓM¬ÛÃöªºÀù³£¥i¾A¥Î¡AGlobo H¦³Ãöªº¨º16ºØÀù¯g³£ÄÝ©ó¤W¥Ö²ÓM¤Þ°_ªºÀùºØ¶Ü¡H¥Ö½§Àù©M¯«¸g¥À²ÓM½F¸ò¤W¥Ö²ÓM¦³Ãö¶Ü¡H16ºØÀùºØ¨ì©³¬Oþ16ºØ¡H ©Ò¨Ï¥ÎªºÁÞ§Ü쬰¦ó¤£§tSSEA-4¡H ¤§«e°Q½×Àù²ÓM¦Ê¤À¤ñ®É ¡A2008¦~ªº½×¤å¤]¥u¤ñ¸ûGH©MSSEA-3¡A2012¦~¦~ªº±M§Q¤å¤~¤ñ¸ûSSEA-3©MSSEA-4 ¡A¬O¦]¬°§ÜGH®a±Ú/§ÜGb5ªº¤ñÈ´N¤w¸g¥i¥H¦³®ÄªºÀË´ú¥X¬O§_¿©Àù¶Ü¡H pºâ§ÜGH/§ÜGb5¡B§ÜBb4/§ÜGb5¡B§ÜBb3/§ÜGb5¡B§ÜBb2/§ÜGb5¥|²Õ¤ñȼƦr¨Ó»P¥¿±`¤Hªº¼Æ¾Ú§@¤ñ¸û¡A§PŪ¬O§_¦³Àù¯g ¬Ý°_¨Ó¥¿±`¤H¤]¥i¥H´ú¥X§ÜGH¡B§ÜGb5¡B§ÜBb4 ¡B§ÜBb3¡B§ÜBb2ªº§ÜÅé¶q¡A¥u¬O¥¿±`¤Hªº¼Æ¾Ú¤ñȸû§C¡A¨ºªí¥Ü³o¨Ç§ÜGH¡B§ÜGb5¡B§ÜBb4 ¡B§ÜBb3¡B§ÜBb2ªº§ÜÅé¶q¤j³¡¤À³£¤£¬O¹s¡AºÃ´bªº¬O¡A¥¿±`¤H¨S¿©Àù¤]¨S¥´822¡A¬°¦ó·|¦³³o¨ÇGH®a±Úªº§ÜÅé¡AÃø¹D¥¿±`¤H°¸º¸¤]·|¥X²{Àù²ÓM¡A³o¨ÇÀù²ÓM¤]¦ñÀHµÛ¢Õ¢Ö¤@°_µo®i¡A¦ý¦bªì´Á´N³Q±j¤jªº§K¬Ì¨t²Îµ¹Äè·À¤F¡A©Ò¥H¤´ºû«ù¨Å骺°·±d¡A¦ý¨Åé¤w¸g¯d¤U¤FGH§ÜÅ骺¬ö¿ý¤F¡H |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/10/22 ¤W¤È 10:45:49²Ä 12 ½g¦^À³
|
¤£¬Oªº Gb5¡]SSEA-3¡^+ sialic acid¡]³è²G»Ä¡^=SSEA-4¡A ©Ò¥H¸Ó½g§@ªÌ¥Îsialyl-Gb5¨ÓºÙ©ISSEA-4µL¥i«p«D¡A¦ýGb5»Psialyl-Gb5©¼¦¹¿W¥ß¡A¨Ã¤£¤¬¬ÛÁõÄÝ©ó¹ï¤è¡C |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2014/10/22 ¤W¤È 09:43:07²Ä 11 ½g¦^À³
|
¦U¦ì¤j¤j¡A¤p§Ì§ä¨ì¤@½g½×¤å http://www.ncbi.nlm.nih.gov/pubmed/24044869 fucosyl-Gb5 = (Globo H) sialyl-Gb5 = (SSEA4) ^¤å§Ú¤£¬O«ÜÀ´¡A¦ý¬O§_¤w¸g§tSSEA-4 ? Abstract ºKn¦p¤U We report here the development of chemoenzymatic methods for the large-scale synthesis of cancer-associated antigens globopentaose (Gb5), fucosyl-Gb5 (Globo H), and sialyl-Gb5 (SSEA4) by using overexpressed glycosyltransferases coupled with effective regeneration of sugar nucleotides, including UDP-Gal, UDP-GalNAc, GDP-Fuc, and CMP-Neu5Ac. The enzymes used in the synthesis were first identified from different species through comparative studies and then overexpressed in E. coli and isolated for synthesis. These methods provide multigram quantities of products in high yield with only two or three purification steps and are suitable for the evaluation and development of cancer vaccines and therapeutics. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/10/22 ¤W¤È 01:41:46²Ä 10 ½g¦^À³
|
µo²{ºÃ¦üOBI-868¡uÁÞ´¹¤ùÀù¯gÀËÅç¸Õ¾¯¡vªº±M§Q¤å¥ó ³o¹ê¦b¤£¬O·s¸ê®Æ¡A¥H«e¨S¦n¦nŪ¡A¥H¬°¬OÁÞ´¹¤ùªº±M§Q±Ôz´N¥u¬O°µ¦sÀÉ¡AµL·N¤¤¤S¦AÂI¨ì¡A»®µMµo²{¨ä¹ê´N¬OOBI-868¡C 2009¦~6¤ë¥Ó½Ð«ØÀÉ¡A2012¦~4¤ë17¤é®Öã±M§Q¡C±M§Q¸¹½XUS 8158367 B2¡A Cancer diagnosis based on levels of antibodies against Globo H and its fragments.¥H§ÜGlobo H¤Î¨ä¤ù¬qªº§ÜÅé°ª§Cµ{«×¬°°ò¦ªºÀù¯g¶EÂ_ http://www.lens.org/images/patent/US/8158367/B2/US_8158367_B2.pdf µo©ú¤Hµn°O¥|¦ì¡A¨Ì§Ç¬O¯Î±Ò´f¡B§d©v¯q¡B¤ý¥¿µX¡B³¯¹a¬z¡C ±M§Q¤å¥ó¤¤¦C¤F¤T½g°Ñ¦Ò¤åÄm¡G¡]À°±z¬d¦n¸ô®|¤F¡^ I. http://www.pnas.org/content/103/1/15.full 2006 II. http://www.pnas.org/content/105/33/11661.full.pdf+html 2008 III. http://www.pnas.org/content/105/33/11667.full 2008 §Úı±oÁÙn¦A¥[¤WIV&V¤~²M·¡¡A¤×¨ä¬OV IV.Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer http://www.pnas.org/content/105/33/11661.full.pdf+html ¡]PDF¥þ¤å¡^¡A²Ä¤@§@ªÌ¬O¤ý¥¿µX V.¦o¦b¥x¤j¥Í¤Æ¬ì¾Ç¬ã¨s©Ò2010¦~³Õ¤h½×¤å¡G ÁÞ´¹¤ù©ó¯e¯f¤§À³¥Î»Pµo®i¡]Glycan Microarray¡GDevelopment and Application in Human Diseases¡^ http://ndltd.ncl.edu.tw/cgi-bin/gs32/gsweb.cgi/ccd=0dvVzX/record?r1=1&h1=0 ÃöÁä¦r¡G¤ý¥¿µX¡C¥þ^¤å¡A¨S¦³¤¤¤åºKn¡C·Q¬Ý¥þ¤åªº¤Hn¶]¤@½ë¹Ï®ÑÀ]¥i¥H¦C¦L/±½´y¡A¦ý½u¤W¤½¶}ÂsÄý/¤U¸ü¶·¦Ü2015/07/26¡C ¦o¦]³o¶µ¬ã¨sºaÀò²Ä¤Q¤E©¡¡y¤ý¥Á¹ç¼ú¡z¤§°ê¤ºÂåÃĬã¨s©Ò³Õ¤h¯ZÀu¨q½×¤å¼ú¡C¡]http://www.genomics.sinica.edu.tw/index.php/tw/20-news/2009-10-26-06-50-10/254-2009-12-17-08-22-15¡^ ³o¤@½gV.¤ñ¸û¸ÔºÉ¡A±M§Q¤å¥óªº¤º®e¤ñ¸û²n¡A¥ú¬Ý±M§Q¤å¤º®e¨ì«á±·|¦³«Ü¦hºÃ°Ý¡A¤£¹L´Nºâ§ÚŪ§¹«á¤]¤´µM¦³ºÃ°Ý¡C µo©úºKn¡G 1.±Ä¼Ë¡G¹ïºÃ±wÀù¯gªº¤H±Ä¦å¡C¡]¦¹Àù¯g¥i¥H¬O¨ÅÀù¡B¶Â¦â¯À½F¡B¯«¸g¥À²ÓM½F¡B¥Ö½§Àù¡B¨xÀù¡BÄáÅ@¸¢Àù¡B§Z±_Àù¡Bµ²¸zÀù¡BGÀù¡BªÍÀù¡B¯ØŦÀù¡^¡CÀËÅéºØÃþ¥iÂX¤j¨ì³è²G¡B²O¤Ú²G¡C 2.µ²¦X¡G§âÀËÅé»P¶î¦³Gb5¡BGH¡BBb2¡BBb3¡BBb4ªºÁÞ´¹¤ù¹å¨|¦b¤@°_¡AÅýÀËÅ餤¥i¯à¦s¦bªº§ÜÀù§ÜÅé»P¥H¤W¤ºØ§Üìµ²¦X¡C 3.´ú¶q¡G´ú¶q»PÁÞ§Üìµ²¦Xªº§ÜÅé¶q¡C 4.§PŪ¡Gpºâ§ÜGH/§ÜGb5¡B§ÜBb4/§ÜGb5¡B§ÜBb3/§ÜGb5¡B§ÜBb2/§ÜGb5¥|²Õ¤ñȼƦr¨Ó»P¥¿±`¤Hªº¼Æ¾Ú§@¤ñ¸û¡A§PŪ¬O§_¦³Àù¯g¡C 쥻¥H¬°¬O§â²{¦³ªºÀù¯g¿zÀ˪º¸~½F¼Ð°O¥þ³£Ån¬A¦b¤ºªº´¹¤ù¡Aµ²ªG¶È¬O¥HGH®a±Ú¬°¥DªºÁÞ§Üì¡CGb3´N¬OSSEA-3¡A¨ä¥LªºBb4¡BBb3¡BBb2³£¬O GH¥hÀY©Î¥h§À«áªº¤ù¬q¡A«á¤TªÌ³£§t©¥Ä¦ÁÞ¡A¦ÓGb5¤£§t©¥Ä¦ÁÞ¡C ¦¹´¹¤ùºë±K«×¥i¹F10ªºt18¦¸¤è§J¡A¤ñ¶Ç²ÎªºELISA§ó±j¡C ºÃ°Ý¡G 1.¦pªG¨üÀ˪̤£¬O¦bGlobo H¦³Ãöªº¨º16ºØÀù¯g¤º¡A¦³¨S¦³®Ä¡H¡]·Ó¤º¤åªº±Ôz³s¥Ö½§Àù¡B¯«¸g¥À²ÓM½F³£¦C¤J¤F¡K¡K¡^ 2.©Ò¨Ï¥ÎªºÁÞ§Ü쬰¦ó¤£§tSSEA-4¡H |
|
|
·|û¡Grabbit10136567 µoªí®É¶¡:2014/10/15 ¤U¤È 01:05:10²Ä 9 ½g¦^À³
|
§O¦A¨¥Á ³æ®è§ÜÅé §K¬Ì¨t²Î ¥i¥H¦X¨Öªº¥h¾\Ū¤@¨Ç¸ê°T ¹ï 888 ¥¼¨Óªº¸ê°T·|¦³À°§U ¤U±ªºµu¤ù ¬O²³æªº§K¬Ì¨t²Î¸Ñ»¡: https://www.youtube.com/watch?v=AA9iNQuhTms "Âù¯S²§©Ê³æ®è§ÜÅé" ´N³Ò·Ð Cliff ©M¨ä¥L±M·~ªº¤j¤j̤F |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2014/10/15 ¤U¤È 12:32:04²Ä 8 ½g¦^À³
|
·PÁÂCliff¤j¡Arabbit¤jªº¤À¨É ·Ç³Æ¥Î¥\¥hÅo¡I |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2014/10/15 ¤W¤È 10:59:30²Ä 7 ½g¦^À³
|
«D±`·PÁÂCliff¤j rabbit¤jªº¼ö¸Û©MµL¨pªº¤À¨É!!! ¯uªºn§V¤O¥Î¥\, ¤~¯à¸ò¤W¥ý¶iªº¸}¨B. |
|
|
·|û¡G¿³Âd¤p¹à¤â10138019 µoªí®É¶¡:2014/10/15 ¤W¤È 10:44:53²Ä 6 ½g¦^À³
|
·PÁÂCliff¤j¤j¸òrabbit¤j¤jªºµL¨p¤À¨É.Åý§Ú¸ò¤j®a¯à°÷¾Ç²ß¦b¾Ç²ß.¨Ó¦n¦nK¤@¤U. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/10/15 ¤W¤È 10:24:06²Ä 5 ½g¦^À³
|
Rabbit¤jªº¦nªF¦è¡Aȱo¾\Ū»P¦sÀÉ¡A ¯E¹©ªº²£«~½u·|«Üªø¥B¼s¡A¨S§â³æ§Ü¡]mAb¡^§ËÀ´¡A¥¼¨Ó·sªF¦è¡]BsAb¡^¥X¨Ó·|¸ò¤£¤W¡C ·PÁ¡C ²q·Q¤j±z¨¥«¤F¡A±z¤£n¼ç¤ô¨º»ò¤[¤~¬O¯uªº¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2014/10/15 ¤W¤È 09:22:44²Ä 4 ½g¦^À³
|
Cliff¤j ±zªº¥Î¥\ ·|Åý§ÚÌı±o¦ÛºF§Î© ±z¤£§[ªº¤À¨É ¤]·|Åý§ÚÌ«å´k ¦¨¬°ª¾ÃѪº¨Ü¾§ ¯uªº«Ü·PÁ±z |
|
|
·|û¡Grabbit10136567 µoªí®É¶¡:2014/10/15 ¤W¤È 09:11:07²Ä 3 ½g¦^À³
|
§Ú¤]¨Ó¦@Á¸²±Á|¡A¤p§Ì´£¨Ñ¤@Ó²³æªº³æ§ÜÅé¤Jªù¸ê®Æ¡AÁöµM¥u¬O¤Jªù¸ê®Æ¡A ¦ý¨ä¹ê¨C¤@¶³£¦³¤£¿ùªºÅå©_¡A¤]Ãö«Y¨ì³¡¤À§Ì§Ì¤½¥qªº¸ê°T¡A«D±`±ÀÂˤj®a¾\Ū¡C http://www2.cmu.edu.tw/~rx50c/Biotechnology_Management/20081203.pdf |
|
|
·|û¡G²´10000155 µoªí®É¶¡:2014/10/15 ¤W¤È 08:16:05²Ä 2 ½g¦^À³
|
¤d¨¥¸U»y¥u¦³¨â¦r§Î®e ·PÁ |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/10/15 ¤W¤È 08:12:41²Ä 1 ½g¦^À³
|
Cliff¤j «D±`·PÁ ¤ÓÆg¤F¡C¡]ÁÙ»¡¨ºÓ¡u¬Ì]¡v©ú¦~·|¸Ñª¼¡^ ¨¯W±z¤F |
|
|
|